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A B S T R A C T
Summer eczema is one of the most common diseases that causes discomfort and impairs the 
quality of life of horses worldwide. This recurrent, insect hypersensitivity-linked allergic pruritus 
affects horses typically during the summer months, when horses are predisposed to insect bites. 
Although horses of various breeds may be affected, this disorder has been demonstrated to be 
more common among some horse breeds than others. The lack of a feasible treatment has made 
equine summer eczema a challenge for veterinary medicine.
   The main aims of this study were to examine serum phospholipids and their use in the 
therapy of summer eczema. The hypotheses were that the profiles of the major serum phospho-
lipids differ between affected and healthy horses and these phospholipids are concentrated in the 
autologous serum preparations applied in therapy depending on the clinical status of the horse. 
Other aims were to delineate clinical features of summer eczema among Finnhorses and the other 
breeds affected in Finland.
   The efficacy of the autoserum preparation in therapy was investigated in 28 horses in a ran-
domized, placebo-controlled and double-blinded study, and the usefulness of this treatment was 
also evaluated according to long-term information collected from the owners of the 343 horses 
treated with this therapy over 12 years. Serum phospholipids and their changes after autoserum 
therapy were analysed in 10 horses with summer eczema and 10 matched healthy controls by 
liquid chromatography coupled with a triple-quadrupole mass spectrometry. Content of phospho-
lipids in autoserum preparations made from the sera of 10 affected and 6 healthy horses were 
analysed by electrospray ionization mass spectrometry. The autoserum preparation was made from 
the horse’s own serum by serial washings to separate water-soluble molecules from water-insol-
uble lipids. Finally, the extracted lipids were mixed with ethanol and absorbed in sugar granules 
for oral administration.
   Horses in the placebo group showed significant aggravation in their clinical signs compared 
with horses treated with autoserum therapy at the same time (P=0.0329). According to long-term 
data from the owners, 70% of the horses treated with an autoserum preparation benefited from this 
therapy (95% CI 0.64-0.75, P<0.0001) and 16% did not, and 14% of the owners did not provide 
a clear opinion. No harmful side effects related to this therapy were observed over the 12-year 
period.
   Horses with summer eczema displayed significantly lower concentrations of phosphati-
dylcholine (P<0.0001) and sphingomyelin (P=0.0115) in their sera than healthy horses. After a 
4-week autoserum therapy, no significant difference in the concentrations of these phospholipids 
between affected horses and their matched controls could be demonstrated. The change in clinical 
signs correlated significantly with the alterations in sphingomyelin concentrations (P=0.0047). 
Of the specific molecular species, sphingomyelin 15:0 showed a significant association with the 
change in clinical status (P=0.0268).
   Analysis of autoserum preparations revealed that these preparations contained major serum 
phospholipids, however, in significantly differing concentrations between horses with summer 
eczema and healthy controls. Affected horses showed more abundant concentrations of phosphati-
dylcholine (P=0.042) and sphingomyelin (P=0.0017) than healthy horses. In addition, concentra-
tions of these phospholipids correlated significantly with the clinical status of the horse (both P 
values <0.001).
   Finnhorses formed the largest group of horses enrolled in this study. Most Finnhorses had be-
come affected with summer eczema before the age of 5 years and showed moderate clinical signs. 
Features of the disease were mainly uniform between Finnhorses and the other affected breeds. 
Severity of the signs was not related to age at onset. No significant correlation existed between 
duration and severity of the disease.
  This study showed that an autoserum preparation containing serum phospholipids was a 
favourable method to treat equine summer eczema. Horses with summer eczema displayed signifi-
cant differentiations in their serum phospholipid profiles and these alterations seemed to change 
according to the clinical status of the horse. Lipids as signalling molecules may become targets of 
intense research also in veterinary medicine, and applications of this autoserum therapy for other 
allergic manifestations of horses should be explored.
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A B B R E V I A T I O N S
AA  arachidonic acid
APC  antigen-presenting cell
ApoM  apolipoprotein M 
CD  cluster of differentiation
CETP  cholesteryl ester transfer protein 
DC  dendritic cell
ELA  equine leucocyte antigen 
ELISA  enzyme-linked immunosorbent assay 
ESI-MS  electrospray ionization mass spectrometry
EV  extracellular vesicle 
FOXP3  forkhead box protein 3
GPCR  G-protein coupled receptor
GWAS  genome-wide association study
HDL  high-density lipoprotein
HL  hepatic lipase
IBH  insect bite hypersensitivity 
IL  interleukin 
LC  Langerhans cell
LCAT  lecithin-cholesterol acyltransferase 
LC-MS  liquid chromatography-mass spectrometry
LDL  low-density lipoprotein
LIR  leucocyte immunoglobulin-like receptor
LPL  lipoprotein lipase
LTP  lipid-transfer protein
lysoPA  lysophosphatidic acid 
lysoPC  lysophosphatidylcholine
MHC  major histocompatibility complex 
MR1 protein MHC class I-related protein
m/z  mass-to-charge ratio 
PA  phosphatidic acid 
PAR2  protease-activated receptor-2
PBMC  peripheral blood mononuclear cell
PC  phosphatidylcholine 
PE  phosphatidylethanolamine 
PI  phosphatidylinositol 
PL  phospholipid
PLTP  phospholipid transfer protein 
PS  phosphatidylserine
RCT  reverse cholesterol transport 
S1P  sphingosine-1-phosphate 
SM  sphingomyelin
SP  substance P
SRM  selective reaction monitoring
TGF-β  transforming growth factor beta
Th1 cell  T helper 1 cell
Th2 cell  T helper 2 cell 
Treg cell  regulatory T cell
TRP  transient receptor potential 
TSLP  thymic stromal lymphopoietin
VLDL  very low-density lipoprotein 
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1 .  I N T R O D U C T I O N
Equine summer eczema is the most common allergic skin disease in horses (Barbet 1992, Scott 
& Miller 2003), manifesting recurrently during the summer months, when animals are exposed to 
biting insects, especially species of Culicoides (Halldorsdottir et al. 1989, Barbet 1992). There-
fore, this disease is also known as insect hypersensitivity or insect bite hypersensitivity (Kurotaki 
et al. 1994, van Grevenhof et al. 2007), although it was firstly named Queensland itch according 
to the place where its relation to these midges was initially described and introduced (Riek 1953, 
Wilson 2014). Currently, equine summer eczema has been documented worldwide in locations 
where Culicoides exist. Iceland is the only country in which summer eczema does not afflict 
horses due to absence of these insects (Broström et al. 1987). However, equine summer eczema is 
commonly found in Icelandic horses exported from Iceland (Halldorsdottir et al. 1989, Björnsdot-
tir et al. 2006), and therefore, this breed has been a target for various investigations related to this 
disorder. Besides Icelandic horses, summer eczema affects horses of multiple breeds, especially 
many native horse breeds (Kurotaki et al. 1994, van Grevenhof et al. 2007, Velie et al. 2016). 
Although the disease has been recognized in Finnhorses for decades, its features have not thus far 
been thoroughly delineated in this breed. 
   Pruritus is the main clinical sign, usually beginning at the mane and tail (Halldorsdottir 
& Larsen 1991, Björnsdottir et al. 2006). Local alopecia, self-excoriation and secondary skin 
infections follow depending on the intensity of scratching, and horses with severe itch may have 
large lesions over the body. Treatment is challenging and no effective therapy exists. Therefore, 
the main aim is to minimize contacts with biting insects by stabling horses during the time when 
insects are active or by using insecticides or special protective blankets. Antihistamines, gluco-
corticoids and diverse skin ointments have been used to relieve clinical signs (Barbet 1992, Scott 
& Miller 2003). However, all available treatments have limitations concerning their efficiency, 
feasibility, side effects or cost. Euthanasia is not an unusual alternative in horses with severe signs 
of summer eczema. In addition, this disease causes great financial loss to owners since the sum-
mer seasons are the best time for riding and other outdoor activities with horses. Equine summer 
eczema is one of the diseases most commonly impairing the quality of life of horses.
   This study originated from the well-known difficulties encountered in the therapy of equine 
summer eczema. The main purpose was to develop and apply a new treatment for this harmful 
disease and to evaluate the efficacy of this therapy according to a randomized, placebo-controlled 
double-blinded study and a long-standing follow-up. In this therapy, a horse’s own serum was 
specifically prepared and used for oral administration. This autoserum therapy is based on the hy-
pothesis that certain serum phospholipids could be involved as signalling molecules in the patho-
genesis of equine summer eczema, and these lipid molecules could also be key players in the 
treatment. Upon specific processing of serum, these phospholipid molecules may be concentrated 
in autoserum preparations. 
   Research on lipids has been activated during the past two decades. Advanced methods to 
analyse and monitor lipids have created pivotal possibilities to unravel the multitude of lipid mol-
ecules involved in various metabolic reactions. At the same time, lipid profiling has become an im-
portant tool to delineate relevant fingerprints typical of distinct human diseases. However, lipids 
and their associations with various disorders have thus far been poorly investigated in horses. The 
development of mass spectrometry combined with modern computer systems has enabled serum 
phospholipids, even when present at minute levels, to be analysed. Here, lipids were analysed both 
in the serum and in the autoserum preparations of horses with summer eczema. In addition, chang-
es in serum lipid profiles were assessed according to alterations in the clinical status of horses.
   The aims of this study were to examine clinical features of summer eczema in native Finn-
horses, to assess efficacy of autoserum therapy and to delineate phospholipids in the serum and au-
toserum preparations and to evaluate their association with the clinical course of summer eczema.
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2 .  R E V I E W 
O F  T H E  L I T E R A T U R E
Features of equine summer eczema
Equine summer eczema, also known as insect hypersensitivity or insect bite hypersensitivity (IBH) 
especially in the scientific literature, is the most common allergic skin disease of the horse (Barbet 
1992, Scott & Miller 2003). It is found worldwide, however, regional differences exist (Riek 1953, 
Broström et al. 1987, Steinman, et al. 2003a, van Grevenhof et al. 2007). Although records of this 
disorder have been found dating back over one hundred years, its relation to biting insects was not 
suggested until 1953 by Riek in Australia. Later, several studies focused particularly on antibodies 
against Culicoides species have supported this aetiology (Halldorsdottir et al. 1989, Hellberg et al. 
2006, Wagner et al. 2006, Langner et al. 2009, Meulenbroeks et al. 2013). The genus of Culicoides 
comprises over one thousand species found worldwide (Huldén et al. 2008). Iceland is the only 
country in which these insects have not been observed (Broström et al. 1987). Different species 
of IBH-linked Culicoides prevail in different parts of the world, C. obsoletus, nubeculosus and 
sonorensis being the main ones (Langner et al. 2008, van der Meide et al. 2013).
   In Finland, this pruritic disorder has been a well-recognized problem in the Finnhorse, a 
native Finnish coldblood breed that has been officially bred over 100 years. Summer eczema has 
been known as “jouhikutka” or “harja-ja häntäkutka” in the early Finnish veterinary literature. It 
was supposed to be associated with the neglected cleaning of the mane and tail, and later, with 
unspecified hypersensitivity reactions (Westermarck 1949, Ora 1963). In Finland, 25 species of 
Culicoides have been recorded (Huldén & Huldén 2014), and of these, particularly Culicoides ob-
soletus has spread throughout the country (Huldén et al. 2008). The major species affecting horses 
have not yet been determined.
   Although horses worldwide are exposed to Culicoides, not all horses develop this allergic 
dermatitis. However, there is a clear tendency for some horse breeds to be more affected than oth-
ers. Usually these horses represent native or local breeds or populations, e.g. Friesian horses and 
Shetland ponies in the Netherlands (van Grevenhof et al. 2007, Schurink et al. 2009) and Exmoor 
ponies in the United Kingdom (Velie et al. 2016). Icelandic horses imported from Iceland are 
particularly prone to this allergy (Halldorsdottir & Larsen 1991). Over the decades, the hereditary 
component of sensitivity to summer eczema has been researched and special interest has been 
targeted to equine leucocyte antigens (ELAs) encoded by genes in chromosome 20 (Halldorsdot-
tir et al. 1991, Lazary et al. 1994, Andersson et al. 2012) and to genetic regions on several other 
chromosomes (Schurink et al. 2012, 2013, Shrestha et al. 2015, Velie et al. 2016). Recent genome-
wide association studies (GWASs) have revealed that most of these regions are linked to immune 
defence reactions (Andersson et al. 2012, Schurink et al. 2013, Shrestha et al. 2015). However, 
no clear and purely hereditary-based background to the outbreak of this disease has emerged. 
Therefore, it is commonly thought that equine summer eczema is a multifactor disease resulting 
from a harmful combination of hereditary susceptibility and environmental influence (Steinman, 
et al. 2003a, van Grevenhof et al. 2007, Andersson et al. 2012, Velie et al. 2016), as in humans 
with atopic dermatitis (Elias & Wakefield 2011, Novak & Leung 2011, Rutkowski et al. 2014).
   The main clinical sign of summer eczema is pruritus (Scott & Miller 2003). Severity of 
secondary skin lesions depends on the intensity of scratching and these lesions are typically found 
in the mane and tail (Halldorsdottir & Larsen 1991), but in severely affected horses also on large 
areas all over the body (Figure 1). Due to an allergic reaction, a variable amount of swelling is 
usually found in the mane, particularly with more advanced disease. Horses show clinical signs 
recurrently during the summer season when insects are active, and these periods vary between dif-
ferent countries. Culicoides have their breeding season when the mean 24-h temperature is 10ºC or 
above (Halldorsdottir & Larsen 1991, Barbet 1992), and in Finland this period, known as thermal 
summer, usually extends from May to September in Turku, or from June to August in Sodankylä, 
the more northern part of the country (Finnish Meteorological Institute 2016). 
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Figure 1. Finnhorse with lesions of summer eczema on large areas in the head.
   Diagnosis of equine summer eczema is based on clinical examination and typical, seasonally 
recurring signs (Broström et al. 1987, Barbet 1992, Scott & Miller 2003, Hellberg et al. 2006, van 
Grevenhof et al. 2007, Olsén et al. 2011). Serological assays for identification of specific aller-
gens have not shown uniform results with intradermal testing and are thus regarded as unreliable 
(Morgan et al. 2007, Langner et al. 2008). Horses with allergic dermatitis usually display positive 
reactions to various antigens both in skin tests (Jose-Cunilleras et al. 2001) and in serological as-
says (Frey et al. 2008) and may also show non-specific inflammatory skin reactions at the site of 
administration (Langner et al. 2008). Neither total serum IgE (Wagner et al. 2003) nor allergen-
specific IgE analysis (Frey et al. 2008) with enzyme-linked immunosorbent assay (ELISA) have 
proven useful for diagnosis since no significant differences have been found between healthy and 
affected horses with these methods. Moreover, concentrations of free serum IgE do not correlate 
with the severity of clinical signs, although higher levels have been detected from the sera of af-
fected horses (Meulenbroeks et al. 2013). Langner et al. (2008) demonstrated that tests based on 
the histamine release from basophils or mast cells are diagnostically more reliable than serological 
assays. However, current techniques with the use of recombinant Culicoides antigens produced in 
E. coli or baculovirus expression systems, instead of crude extracts, have provided new and more 
accurate diagnostic tools to distinguish healthy and affected horses (Langner et al. 2009, van der 
Meide et al. 2013). The diversity of Culicoides species and the cross-reactivity between these 
antigens (Langner et al. 2009, van der Meide et al. 2013) render execution of these studies some-
what challenging. The main differential diagnoses of summer eczema are parasitic skin diseases, 
dermatophytosis and other allergic disorders (Barbet 1992, Scott & Miller 2003).
   Treatment of this allergy is difficult. The main principle is to avoid contact with biting in-
sects. However, total isolation is impossible to achieve since the summer months are otherwise 
the best time for outdoor activities with horses. Special blankets, insecticides, glucocorticoids, 
antihistamines and various kinds of skin ointments are the most commonly used treatments (Bar-
bet 1992, Scott & Miller 2003, Björnsdottir et al. 2006, Schaffartzik et al. 2012, Wilson 2014). 
Unfortunately, none of the available therapies have been uniformly beneficial, and all have limita-
tions relating to efficacy, feasibility, side effects or cost. Special blankets have been designed for 
protection from bites, and their use in combination with overnight stabling has been demonstrated 
to be a significantly more favourable measure than either a blanket or overnight stabling alone 
(Olsén et al. 2011). Insecticides have been used for decades and their disadvantage is a rather short 
evaporation time (Barbet 1992). Medical treatment has been based on the use of glucocorticoids 
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and antihistamines. However, both of these medications have disadvantages; glucocorticoids due 
to detrimental side effects (Barbet 1992, Foster et al. 1998, Schaffartzik et al. 2012) and antihis-
tamines due to low bioavailability after oral administration (Barbet 1992, Foster et al. 1998, Di-
rikolu et al. 2008, Olsén et al. 2008, Kuroda et al. 2013) and poor efficacy relative to placebo treat-
ment (Olsén et al. 2011). Immunotherapy has been used occasionally, but without marked success 
(Barbet 1992, Ginel et al. 2014), although Anderson et al. (1996) did describe strongly positive 
outcomes in six of the 10 severely affected horses that were subcutaneously treated with whole-
body Culicoides extracts combined with a mycobacterial cell wall adjuvant. Besides these crude 
whole-body preparations (Barbet 1992, Anderson et al. 1996), commercial Culicoides extracts 
that are currently available, have been used. Ginel et al. (2014) conducted a placebo-controlled 
study by using these commercial Culicoides antigens combined with other environmental aller-
gens adjusted according to horses’ positive reactions to the commercial ELISA, but they observed 
no significant benefit from this therapy. Preventive immunization schedules with recombinant 
antigens have been recently introduced in both humans (Valenta et al. 2012) and horses (Jonsdottir 
et al. 2015). The idea of this approach for horses is to immunize Icelandic horses already in Iceland 
before export, thereby probably managing to avoid the outbreak of summer eczema. This process 
is in its pilot phase (Jonsdottir et al. 2015).
Immune responses in allergic reactions of the skin 
and in equine summer eczema
The skin is an important organ for sensing various environmental antigens and together with the 
gastrointestinal tract represents the first sentinel against foreign intruders and substances (Scott & 
Miller 2003, Chinthrajah et al. 2016). Cells assembling in allergic reactions are situated in both the 
epidermis and the dermis (Scott & Miller 2003, Kendall & Nicolaou 2013), and immune cells are 
also recruited from the circulation when necessary (Galli et al. 2008). In the epidermis, Langer-
hans cells (LCs) are the main cell group participating in immune responses (Ginhoux & Merad 
2010). Keratinocytes collaborate by producing a variety of cytokines and lipid mediators (Scott & 
Miller 2003, Kawakami et al. 2009, Kendall & Nicolaou 2013). LCs are classified as a subgroup 
of dendritic cells (DCs) (Clausen & Kel 2010, Ginhoux & Merad 2010, Otsuka & Kabashima 
2015), and despite many similarities with classical DCs, LCs have features that distinguish them 
from DCs, which predominate in the dermis (Ginhoux & Merad 2010, Haniffa et al. 2015). For 
example, proliferation and differentiation of these cells follow different routes (Ginhoux & Merad 
2010, Haniffa et al. 2015). However, both of these cell types are known as antigen-presenting cells 
(APCs) (Clausen & Kel 2010, Ginhoux & Merad 2010). LCs recognize antigens in the epidermis 
and transport these captured molecules to regional lymph nodes for presentation to naive T cells 
(Clausen & Kel 2010, Dubrac et al. 2010). It has been demonstrated that migrated APCs are de-
tected in the draining lymph nodes 18 hours after antigen challenge (Sokol et al. 2008). Both LCs 
(Clausen & Kel 2010, Ginhoux & Merad 2010) and DCs (Steinman et al. 2003b) express major 
histocompatibility complex (MHC) class II molecules, through which protein antigens are pre-
sented. Depending on the amount of antigen, either LCs or DCs will be activated for presentation, 
LCs being more sensitive against low antigen doses (Bacci et al. 1997). There is evidence that DCs 
regulate the balance of immune responses, especially deleting extraneous T cells and/or promot-
ing the expansion of regulatory T (Treg) cells, after antigen presentation has been accomplished 
(Steinman et al. 2003b, Chinthrajah et al. 2016). In addition to antigen-presenting MHC mol-
ecules, APCs express CD1 (cluster of differentiation) molecules that are specialized in presenting 
lipid antigens (Jayawardena-Wolf & Bendelec 2001, Leslie et al. 2008, De Libero & Mori 2010, 
Salio et al. 2010, Girardi & Zajonc 2012, Adams 2014), and distinct MHC class I-related (MR)1 
proteins, which in turn are associated with small antigen molecules for T cell presentation (Layre 
et al. 2014, Pierce  et al. 2014, Birkinshaw et al. 2015). Lipid and glycolipid antigens are firstly 
sorted by extra- and intracellular lipid-transfer proteins, LTPs (Mori & De Libero 2008), and de-
pending on, for example the length and unsaturation degree of acyl chains these lipid antigens are 
presented via different types of CD1 molecules on the plasma membrane of APCs (Jayawardena-
Wolf & Bendelec 2001, De Libero & Mori 2010, Layre et al. 2014, Birkinshaw et al. 2015). These 
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targets for lipids were not described until the late 1980s by Porcelli et al. (Porcelli et al. 1989, De 
Libero & Mori 2010), and in recent years comprehension of CD1 molecules and their function 
has grown enormously (Jayawardena-Wolf & Bendelec 2001, De Libero & Mori 2010, Salio et al. 
2010, Jyonouchi et al. 2011, Birkinshaw et al. 2015). 
   In addition to APCs, mast cells have an important role in dermal immune defences, espe-
cially in allergic responses (Olivera & Rivera 2005, Silveira e Souza et al. 2011). Mast cells are 
stimulated when allergens bind to IgE, leading to crosslinking of FcεRI receptors, the high-affinity 
receptors for IgE on the plasma membrane of mast cells (Kawakami & Galli 2002, Price et al. 
2008, Galli et al. 2011). This crosslinking of captured FcεRI receptors induces a degranulation of 
mast cells, followed by leakage of histamine and other inflammatory mediators, including pros-
taglandins and leukotrienes (Boyce 2007, Metcalfe et al. 2016). These substances are released 
within minutes after FcεRI activation (Gould et al. 2003, Kulinski et al. 2015) and are responsible 
for the clinical signs, such as oedema, erythema and pruritus, associated with an allergic reaction 
(Galli et al. 2008). Sphingosine-1-phosphate (S1P) is an important lipid mediator of mast cells 
that is produced later after FcεRI aggregation (Kulinski et al. 2015). This bioactive sphingolipid 
derivative acts in an autocrine and paracrine fashion not only by regulating mast cells (Price et al. 
2008, Olivera & Rivera 2011) but also by controlling migration of APCs to lymph nodes (Reines 
et al. 2009) and promoting the egress of lymphocytes from lymphoid organs (Cyster & Schwab 
2012, Maceyka & Spiegel 2014). In an allergy-focused milieu, S1P modifies T-cell functions, es-
pecially towards responses of T helper 2 (Th2) cells (Olivera & Rivera 2011), but also has a role 
in the maturation and behaviour of Treg cells (Cyster & Schwab 2012).
   After antigen presentation by APCs and release of mediators by mast cells and the other in-
flammatory cells involved, T cells are induced towards a Th2 phenotype, and these T cells in turn 
stimulate B lymphocytes to produce more allergen-specific IgE, leading to further crosslinking 
with IgE-loaded FcεRI receptors and the antigen on mast cells (Kawakami & Galli 2002, Galli et 
al. 2008). Simultaneously, other leucocytes, such as basophils and eosinophiles, are recruited from 
the circulation at the site of inflammation (Galli et al. 2008), and, additionally, basophils from the 
circulation migrate to the draining lymph nodes, where they promote Th2 skewing after allergen 
challenge (Sokol et al. 2008). The role of basophils has long been ignored (Falcone et al. 2006, 
Min & Paul 2008); however, these cells have recently been demonstrated to participate in various 
pivotal phases during allergic responses (Mukai et al. 2005, Falcone et al. 2006, Schneider et al. 
2010). Besides mast cells, basophils express FcεRI receptors, but also leucocyte immunoglobulin-
like receptors (LIRs) through which basophils are either activated (LIR7) or inhibited (LIR3) to 
release histamine, cysteinyl leukotrienes and interleukin (IL)-4 (Sloane et al. 2004). Thus, being 
stimulated via LIRs, basophils are able to act independently from IgE-mediated crosslinking with 
FcεRI receptors (Sloane et al. 2004). Moreover, LIR3 is able to link with LIR7 and FcεRI, result-
ing in inhibition of these receptors and their related mediators (Sloane et al. 2004). Taken together, 
populations of both innate and adaptive immune cells are implicated in the later stages of allergic 
reactions (Galli et al. 2008, Schneider et al. 2010).   
   Of the cytokines assembling in allergic responses, IL-4 and IL-13 are the most important 
for promoting inflammation (Akdis et al. 2005, Galli et al. 2008, Matsuoka et al. 2013), while 
IL-10, transforming growth factor (TGF)-β (Akdis et al. 2005, Sakaguchi et al. 2009, Schmet-
terer et al. 2012, Chinthrajah et al. 2016) and IL-2 are associated with suppression, IL-2 actually 
being involved in the differentiation of Treg cells (Sakaguchi et al. 2009, Josefowicz et al. 2012). 
Matsuoka et al. (2013) have recently introduced an additional inhibitory cytokine, IL-27, which is 
produced by DCs and targeted for Th2 suppression. Of the promoting cytokines, IL-4 is particu-
larly linked to Th2 skewing (Falcone et al. 2006, Sokol et al. 2008), likewise thymic stromal lym-
phopoietin (TSLP) produced by basophils (Sokol et al. 2008, Otsuka & Kabashima 2015). Various 
cell types assembling in allergic inflammations are able to secrete these substances depending on 
the status of responses (Galli et al. 2008, Schmetterer et al. 2012). Studies on cultured peripheral 
blood mononuclear cells (PBMCs) from horses with and without summer eczema have shown that 
the concomitant expressions of IL-10 and TGF-β down-regulate IL-4-producing cells and these 
cells are more pronounced in cultures of horses with summer eczema (Hamza et al. 2008).
   Treg cells are a specific lineage of T cells that participate in the regulation of immune re-
sponses (Akdis et al. 2005, Sakaguchi et al. 2009, Schmetterer et al. 2012, Kratzer & Pickl 2016). 
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These cells are differentiated from the other T cell types according to their CD molecules and an 
expression of the transcription factor, forkhead box protein 3 (FOXP3) (Sakaguchi et al. 2009, 
Schmetterer et al. 2012). The phenotype of CD4+CD25+FOXP3+CD127- is currently considered 
to represent an exact definition for naturally occurring Treg cells (Schmetterer et al. 2012). Treg 
cells produce IL-10 and TGF-β (Akdis et al. 2005), and these cytokines in turn prevent activation 
of LCs and DCs (Sakaguchi et al. 2009, Schmetterer et al. 2012), which is essential for the pro-
motion of Th2 responses and sustenance of allergic disorders (Clausen & Kel 2010, Dubrac et al. 
2010). Additionally, Treg cells express various cell-surface molecules that promote their suppres-
sive actions by, for example, abrogating effector T cells from interactions with APCs (Sakaguchi 
et al. 2009, Schmetterer et al. 2012).
   Normally, the immune responses occurring after contact with various allergens are self-lim-
iting without noxious consequences (Gould et al. 2003, Wilson 2014) and are controlled by inter-
actions between APCs, mast cells and Treg cells, leading to tolerance against innocuous antigens 
(Steinman, et al. 2003b, Price et al. 2008, Reines et al. 2009, Sakaguchi et al. 2009, Chinthrajah 
et al. 2016). Responses to bites of insects are usually local and transient and are classified as type 
I or immediate hypersensitivity reactions, resulting mainly from mast cell activation (Kurotaki 
et al. 1994, Scott & Miller 2003, Wagner et al. 2006, Wilson 2014). However, in horses with 
summer eczema these responses are prolonged as horses are exposed to allergens (Wilson 2014), 
leading to high IgE levels, continuous antigen presentation to T cells with subsequent Th2-cell 
polarizations (Hellberg et al. 2006, Heimann et al. 2011, Meulenbroeks et al. 2015) and finally a 
possible switch towards a delayed, type IV hypersensitivity state (Kurotaki et al. 1994, Scott & 
Miller 2003, Schaffartzik et al. 2012). Actually, both of these hypersensitivity types seem to exist 
simultaneously (Meulenbroeks et al. 2015). 
   It has been demonstrated recently that in affected horses the balance between Th2 and Treg 
cells is disturbed, and this asymmetry may be pivotal in the pathogenesis of summer eczema (Hei-
mann et al. 2011, Hamza et al. 2012), as has been observed also in allergic humans (Akdis et al. 
2005). Although healthy horses and horses with summer eczema have not shown differences in the 
amounts of Treg cells in the circulation (Hamza et al. 2012) or in skin biopsies (Meulenbroeks et 
al. 2013), affected horses are incapable of elevating the number of Treg cells after antigen stimula-
tion, while healthy horses develop a significant increase of these cells (Hamza et al. 2012). This 
was suggested to be the result of the excessive IL-4 secretion detected in eczema horses (Hamza et 
al. 2012). A more recent study has demonstrated that also T helper 1(Th1)-cell polarization seems 
to prevent IBH since healthy horses respond more commonly with Th1 skewing to allergen chal-
lenge (Meulenbroeks et al. 2015).
   Kurotaki et al. (1994) distinguished three stages in the progression of histopathological 
changes related to insect hypersensitivity. The initial phase comprises epidermal intercellular 
oedema, an increase in the number of LCs and perivascular infiltrations of eosinophils and mast 
cells. In the more advanced stage, the number of mast cells and eosinophils increase further, si-
multaneously with infiltrating T cells and DCs in the dermo-epidermal junction, and finally, when 
clinical signs start to regress along with cooling weather conditions, hyperkeratosis and epidermal 
hyperplasia present (Kurotaki et al. 1994). Van der Haegen et al. (2001) described similar acute-
phase changes with an abundance of eosinophils, mast cells and lymphocytes, and Meulenbroeks 
et al. (2015) demonstrated that these reactions were more pronounced in affected horses, even in 
wintertime when IBH-affected horses were subjected to the intradermal challenge of Culicoides 
antigens. 
   Atopic dermatitis of humans has many features in common with equine summer eczema. 
Intense pruritus, excessive IgE-mediated sensitization and Th2 polarization are typical findings of 
both disorders (Jose-Cunilleras et al. 2001, Dubrac et al. 2010, Elias & Wakefield 2011, Heimann 
et al. 2011, Novak & Leung 2011, Schaffartzik et al. 2012). In addition, their histopathological 
pictures have many similarities (Kurotaki et al. 1994, Kawakami et al. 2009). In humans, disturbed 
epidermal barrier function due to inherited defects of filaggrin protein is one of the main predis-
posing factors making the skin more sensitive to external intruders (Proksch et al. 2003, Elias & 
Wakefield 2011, Novak & Leung 2011). In horses, this has not yet been investigated (Schaffartzik 
et al. 2012).
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Mechanisms of pruritus
Pruritus is the main clinical manifestation of equine summer eczema. Therefore, it is important 
to understand the mechanisms underlying itch. Pruritus that originates purely from the skin and 
affects only the skin is categorized as pruritoceptive itch, as opposed to neurogenic, psychogenic 
and neuropathic itch, the initial causes of which are unrelated to skin disorders (Patel & Dong 
2011, Garibyan et al. 2013). Pruritus is transmitted via sensory nerves that protrude their fibres 
into the epidermis, while the bodies of these cells are situated in the dorsal root ganglia in the 
vicinity of the spinal cord (Steinhoff et al. 2006, Garibyan et al. 2013). The endings of these un-
myelinated C-fibres express receptors and ion channels that convey itch signals following interac-
tions with pruritogens, the mediators of pruritus (Garibyan et al. 2013). In the next phase, nerve 
impulses are conducted with spinal neurons and finally received in the brain (Steinhoff et al. 2006, 
Garibyan et al. 2013). Debate exists as to whether itch and pain stimuli possess the same nerve 
routes or whether there are specific neurons for each impulse (Patel & Dong 2011, Garibyan et al. 
2013). However, current understanding supports the theory that both types of neurons exist, and 
itch-sensitizing neurons are a subset of pain neurons that are activated when the stimulus does not 
reach the threshold of the pain stimulus (Oude Elferink et al. 2011, Patel & Dong 2011, Garibyan 
et al. 2013).
   Various cells and pruritogens are able to communicate with nerve endings and to contribute 
to the sense of pruritus (Steinhoff et al. 2006). Histamine is the main cause of itching by stimu-
lating cutaneous sensory nerves (Gould et al. 2003, Ohsawa & Hirasawa 2014), although mast 
cell tryptase is also suggested to have pruritogenic effects (Kawakami et al. 2009). In addition, 
substance P (SP) of mast cells and IL-31 of Th2 cells are mediators of pruritus (Garibyan et al. 
2013). Tryptase has been detected also in mast cells from horses with IBH (van der Haegen et al. 
2001). All of these pruritogens have their own targets on the nerve endings, e.g. G-protein coupled 
receptors (GPCR) H1 and H4 for histamine (Garibyan et al. 2013, Ohsawa & Hirasawa 2014), 
protease-activated receptor (PAR)-2 for tryptase, neurokinin receptors for SP and IL-31 receptors 
for IL-31 (Steinhoff et al. 2006, Patel & Dong 2011, Garibyan et al. 2013). The exact mode for IL-
31 action is thus far obscure since IL-31 has receptors both on the sensory nerves and in the plasma 
membrane of keratinocytes (Steinhoff et al. 2006). In addition to specific receptors, stimuli to 
nerve cells are mediated via the ion channels of the transient receptor potential (TRP) family (Gar-
ibyan et al. 2013). When the receptors or ion channels are activated, sensory nerve endings release 
neuromediators, transferring itch signals to the spinal cord and the brain (Steinhoff et al. 2006).
   Keratinocytes seem to be additional key players in the circuit of pruritus. These cells are in a 
close contact with sensory nerve endings and express receptors and ion channels involved in con-
duction of itch stimulus (Steinhoff et al. 2006, Garibyan et al. 2013). Moreover, keratinocytes are 
able to release both enhancing and suppressing mediators (Steinhoff et al. 2006). Keratinocytes 
are currently the focus of intense research (Garibyan et al. 2013). Taken together, various cell 
types and their mediators are involved in the mechanism of pruritus. Therefore, therapies based 
only on the use of antihistamines have usually shown limited effects on both horses and humans 
with allergic skin diseases (Olsén et al. 2011, Garibyan et al. 2013).
  
General aspects of phospholipids and their roles in allergy
Lipids and phospholipids
Lipids are a diverse group of molecules that act as the main structural components of cellular 
membranes (van Meer 2011, Holthuis & Menon 2014). Lipids also participate in various intra- and 
extracellular reactions, including inflammation, apoptosis, cell signalling and a plethora of hormo-
nal and enzymatic activities (Subbaiah & Liu 1996, van Meer 2005, Fadeel & Xue 2009, Blom et 
al. 2015). The defining feature of lipids is their insolubility in water, an ability that enables them 
to form bilayer membranes (Nelson & Cox 2008, Holthuis & Menon 2014) and serve as a corner-
stone for the existence of uni- and multicellular organisms. To date, biological lipids are divided 
into eight main groups, including fatty acids, glycerolipids, glycerophospholipids, sphingolipids, 
sterol lipids, prenol lipids, saccharolipids and polyketides, of which glycerophospholipids and 
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sphingolipids are also known as phospholipids (PLs) (Nelson & Cox 2008, Bublin et al. 2014). 
The cellular lipidome – the total set of lipid molecules in the specific cell types – comprises more 
than 1000 distinct lipids, and in the plasma, there are thousands of lipid species (Quehenberger et 
al. 2010, van Meer & de Kroon 2011). Of the content in human plasma, lipids represent the major-
ity of biological molecules (Quehenberger & Dennis 2011). 
   PLs are composed of a polar head group, including a phosphate group and its substitute, two 
acyl chains and a glycerol backbone in glycerophospholipids or one acyl chain and a sphingosine 
backbone in sphingolipids (Nelson & Cox 2008). The polar head group defines the class of PLs 
and based on their acyl chain composition, i.e. the degree of unsaturation and the length of acyl 
chains, PLs are distinguished into different molecular species (Nelson & Cox 2008). The nomen-
clature of species is based on the total number of carbon atoms and double bonds in acyl chains 
(Nelson & Cox 2008), i.e. PC 36:2 has 36 carbon atoms with 2 double bonds in acyl chains. The 
main PL classes found in mammalian cells and circulation are phosphatidylcholine (PC), phos-
phatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid 
(PA) and sphingomyelin (SM) (van Meer 2005, Quehenberger & Dennis 2011). PLs constitute 
the second largest group of lipids in human plasma; only sterol lipids, in major part as cholesterol 
existing in esterified or non-esterified forms (Nelson & Cox 2008), are found more abundantly 
(Quehenberger & Dennis 2011). Of the PLs, PC and SM are the most abundant in horse serum, 
while PE and PI have been detected at minor levels (Fuchs et al. 2009).
Phospholipids as structural components of membranes and circulating lipoproteins
PLs are enriched in the plasma membrane, where they form a bilayer barrier between extra- and 
intracellular spaces (Kierszenbaum 2002). In this bilayer, lipids are settled so that their hydro-
phobic acyl chains are towards the inner side of this bilayer, while the polar head groups are at 
the outer side (Kierszenbaum 2002, Holthuis & Menon 2014). As a result, the plasma membrane 
has two leaflets, outer and inner, and these leaflets have their own specific lipid compositions 
(Kierszenbaum 2002, van Meer 2011). This lipid asymmetry is crucial for the transmembrane 
trafficking of the cell (Fadeel & Xue 2009, van Meer 2011). PC and SM are the major PLs in the 
outer leaflet, whereas PS, PE, PI and PA prefer the inner leaflet (Kierszenbaum 2002, Nelson & 
Cox 2008, Silveira e Souza et al. 2011). In addition to the plasma membrane, PLs are enriched in 
intracellular membranes, such as endoplasmic reticulum, where their compositions and amounts 
depend on the organelles and activities involved (Holthuis & Menon 2014).
   In the mammalian circulation, lipids are carried mainly as a part of lipoprotein particles (Fig-
ure 2) (Shepherd 1991, Watson et al. 1993), whereas free fatty acids are bound to albumin (Watson 
et al. 1993). Lipoprotein particles (Figure 2) consist of surface-amphipathic apolipoproteins and 
specific compositions of lipids, including cholesterol, cholesteryl esters, triglycerides and PLs 
(Watson et al. 1991, Watson et al. 1993). Four classes of plasma lipoproteins have been identified 
in horses (Shepherd 1991, Watson et al. 1993). High-density lipoprotein (HDL) is the major class 
in horses, accounting about 60% of the total lipoprotein mass, and with low-density lipoprotein 
(LDL) they are the main carriers of cholesterol and PLs (Watson et al. 1991). In contrast to HDL or 
LDL, very low-density lipoproteins (VLDLs) and chylomicrons are triglyceride-rich lipoproteins, 
mostly involved in energy metabolism (Watson et al. 1991, 1993). Chylomicrons carry dietary 
lipids supplied from the intestine, whereas VLDL transports endogenous triglycerides derived 
from the liver (Watson et al. 1993).  Equine VLDL contains both small and large molecular apoli-
poproteins (Watson et al. 1993). In addition to lipoproteins, blood contains lipid molecules that are 
bound in vesicular structures such as extracellular vesicles (EVs); however, their lipid content is 
low in comparison with that in lipoproteins (Caby et al. 2005, Bobrie et al. 2011, Chaput & Théry 
2011, Raposo & Stoorvogel 2013). 
   Phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) regulate 
trafficking between circulating lipoproteins (Guyard-Dangremont et al. 1998, Zannis et al. 2015). 
Unlike humans, horses have not shown CETP activity (Watson et al. 1993, Guyard-Dangremont et 
al. 1998). In addition to PLTP, equine lipid homeostasis is controlled by lecithin-cholesterol acyl-
transferase (LCAT) and lipolytic enzymes such as lipoprotein lipase (LPL) and hepatic lipase (HL) 
(Watson et al. 1993). Breed, gender or a postprandial stage has shown no relation to the activity of 
LCAT, LPL or HL in adult horses (Watson et al. 1993). 
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   In intracellular spaces, lipids are transported via both vesicular structures and specific LTPs 
(Mori & De Libero 2008, Wong et al. 2017).  LTPs organize intracellular trafficking of PLs by ex-
tracting lipid molecules from membranes and by transporting them between organelles (Holthuis 
& Menon 2014, Wong et al. 2017). Some LTPs are specialised for particular lipids, while others 
carry various types of lipid molecules (Wong et al. 2017).
Figure 2. Simplified model of lipid transport between the intestinal lumen, circulation and tissues (modified 
from Shepherd 1991, Watson et al. 1991, Zannis et al. 2015). Chylomicrons derived from dietary lipids are 
postprandially hydrolysed by lipoprotein lipase (LPL) in the circulation. Generated free fatty acids are direct-
ed to adipose tissue for storage or to muscles to be used for energy production, while chylomicron remnants are 
cleared by the liver. Very low-density lipoproteins (VLDLs) are synthesized in the liver and in the circulation, 
they are converted to low-density lipoproteins (LDLs) in a process catalysed by LPL and hepatic lipase (HL). 
High-density lipoproteins (HDLs), which are mainly synthesized in the liver, recycle cholesterol from peripher-
al tissues back to the liver where extra cholesterol is secreted in the bile. This is known as the reverse cholesterol 
transport (RCT) process. Lipoproteins are the principal lipid carriers in the circulation. The major lipids carried 
in lipoprotein particles are cholesteryl esters, free cholesterol, triglycerides and various phospholipids. Apolipo-
proteins are major structural components on the particle surface and due to their amphipathic nature they are re-
sponsible for solubilisation of lipids. A detailed structure of the lipoprotein particle is presented. 
Phospholipids in allergic inflammation
Membrane PLs are a prime source of arachidonic acid (AA), the precursor for both various pro- 
and anti-inflammatory lipid mediators such as eicosanoids, endocannabinoids and lipoxins (Boyce 
2007, Bannenberg & Serhan 2010, Serhan & Petasis 2011, Kendall & Nicolaou 2013, Demetz et 
al. 2014). In inflammatory conditions, these bioactive lipids act in a paracrine or autocrine fashion, 
usually at nanomolar concentrations (Boyce 2007, Bannenberg & Serhan 2010, Stables & Gilroy 
2011). In inflammation and its resolution, lipid mediators co-operate iteratively to restore homeo-
stasis (Serhan & Petasis 2011, Stables & Gilroy 2011, Fanning & Boyce 2013).
   Of the major PLs, PC is usually profiled as a structural lipid and a source for production of 
other lipids, whereas SM has essential functions related to epidermal barrier metabolism and sig-
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nalling in allergic reactions (Proksch et al. 2003, Price et al. 2008).  SMs are important precursors 
of S1P, the pivotal lipid mediator produced by mast cells in allergic responses (Price et al. 2008, 
Olivera & Rivera 2011, Kulinski et al. 2015). After activation of FcεRI receptors, S1P is generated 
by sphingosine kinases in mast cells and released for the engagement with G-protein coupled S1P 
receptors on the membrane of the parent cells and nearby cells (Olivera & Rivera 2005, Price et al. 
2008, Kolter 2011, Hanson et al. 2012, Maceyka & Spiegel 2014, Kulinski et al. 2015). Five types 
of S1P receptors, numbered from S1P1 to S1P5, have been identified (Reines et al. 2009, Chun et 
al. 2010). These receptors comprise differing numbers of amino acids and their engagements result 
in distinct influences (Chun et al. 2010). For example, the binding site on the S1P1 receptors is 
highly sensitive to hydrophobicity of the ligand (Hanson et al. 2012). The concentration gradient 
of S1P between blood and tissues is continuously maintained since decreased blood levels subject 
one to lymphopenia (Price et al. 2008, Kulinski et al. 2015). Erythrocytes are the main source of 
blood S1P (Price et al. 2008, Cyster & Schwab 2012). In the circulation, S1P is bound to albumin 
and apolipoprotein M (apoM) in HDL, apoM being the main and specific carrier for S1P (Christof-
fersen et al. 2011). The ability of S1P to affect APC and lymphocyte trafficking has created new 
therapeutic options for use of S1P receptors (Reines et al. 2009, Cyster & Schwab 2012), particu-
larly in the treatment of autoimmune disorders (Maceyka & Spiegel 2014). 
   Since lipids participate in various metabolic reactions at different steps in mammalian bi-
ology, these molecules are involved in a wide range of disorders. As already mentioned, PL de-
rivatives are key players in inflammation and its resolution, and therefore, disturbances in their 
metabolism are associated especially with immune-mediated afflictions, of which allergies and 
autoimmune responses are the most common (Kolter 2011, Jovanovic et al. 2013, Korematsu et 
al. 2014, Lis-Swiety et al. 2014, Maceyka & Spiegel 2014). In skin allergies, particularly in at-
opic disorders, PL derivatives have roles as both structural components of skin and regulators of 
allergic responses. Ceramides are the main components of the epidermal lipid barrier and active 
metabolites derived from SM (Proksch et al. 2003, Kolter 2011, Olivera & Rivera 2011, Maceyka 
& Spiegel 2014). Production of ceramides and SM is linked, since ceramides can be synthesized 
from SM and vice versa (Kolter 2011, Maceyka & Spiegel 2014). Ceramides protect skin from 
excess water loss (Proksch et al. 2003, Kolter 2011) and ceramides detected in the epidermis have 
typically long acyl chains (Kolter 2011). SM is a precursor for two of the seven types of ceramides 
identified in the skin (Proksch et al. 2003). In atopic disorders, an altered SM metabolism leads to 
disturbed production of ceramides, resulting in defects in barrier integrity (Proksch et al. 2003). In 
the atopic skin, the amount of ceramide has been demonstrated to be lower than in the healthy skin 
(Proksch et al. 2003). Apart from the skin, ceramides have an important role in the endothelium by 
responding to various inflammatory signals (Maceyka & Spiegel 2014). Intriguingly, SM seems 
to be involved in allergic reactions also as a part of allergens, especially in dairy products, where 
they promote the secretion of Th2 skewing cytokines (Jyonouchi et al. 2011). 
   Although lipids play an essential role in many biological reactions (van Meer 2005, Nelson 
& Cox 2008, Inouye et al. 2010, Serhan & Petasis 2011) and PLs form a marked constituent of 
lipids present in mammalian serum lipoproteins (Quehenberger & Dennis 2011), involvements of 
lipids and their changes under various pathological conditions are still poorly understood (Sub-
baiah & Liu 1996, Quehenberger et al. 2010, van Meer 2011, Lin et al. 2016). This is mainly 
due to the wide diversity of lipids in living organisms (Quehenberger et al. 2010) and the earlier 
deficient methods to identify this multitude of specific lipid species (Hirvisalo & Renkonen 1970, 
Nelson & Cox 2008, Hammad et al. 2010). However, the recent development of mass spectrom-
etry combined with modern software applications has made it possible not only to differentiate 
and quantify lipid compositions in various cell organelles and biochemical reactions (Hermansson 
et al. 2005, van Meer 2005, Shaner et al. 2009, Hammad et al. 2010, Harkewicz & Dennis 2011, 
Kainu 2012, Batchu 2016) but also to monitor lipids as biomarkers in health and disease (Fuchs 
et al. 2005, Qu et al. 2012, Quintana et al. 2012, González-Dominguez et al. 2014, Li et al. 2014, 
Patel et al. 2014, Vinding et al. 2015). 
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3 .  A I M S  O F  T H E  S T U D Y
There were two major aims in the present thesis. The first aim was to examine serum PLs and their 
therapeutic use in horses with summer eczema. The preliminary hypotheses were that profiles of 
the major serum PLs differ between affected and healthy horses and these PLs typical of the horse 
are present in autologous serum preparations used in therapy of the disease. The second major aim 
was to delineate clinical features of summer eczema in Finnhorses. Specific aims were as follows:
1. To delineate characteristics of summer eczema among Finnhorses and other breeds 
 affected in Finland (I).
2. To evaluate feasibility of autoserum therapy based on the results of the placebo-
 controlled double-blind study (II) and long-term information collected for 
 this treatment (III).
3. To analyse PL compositions both in autologous serum preparations (IV) and in sera 
 of horses with summer eczema and healthy controls and to assess whether these lipid 
 profiles change after therapy (V).
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4 .  M A T E R I A L S 
A N D  M E T H O D S
Horses
Altogether 363 horses with clinical signs of summer eczema and 16 healthy controls were in-
cluded in this work comprising a series of studies performed in 1997-2014. Features of the disease 
were delineated in 275 horses between 1997 and 2007 (Study I), whereas studies on autoserum 
therapy comprised 343 horses and were carried out in 1997-2008 (Studies II and III). Of these 343 
horses, 28 participated in the randomized, placebo-controlled and double-blinded study performed 
in 1997-1998 (Study II), and additionally, Study II included 39 horses treated with autoserum 
preparation but not placebo controlled. Besides the 67 horses participating in Study II, there were 
276 horses in Study III that had not participated in the earlier studies. Taken together, Study III 
comprised 343 horses and this study was carried out to obtain long-term clinical experience of 
autoserum therapy. Serum PLs were analysed from autoserum preparations of 10 affected and 
6 healthy horses in 2012 (Study IV). Differences in serum PLs and changes after therapy were 
examined between the 10 horses with summer eczema and their 10 matched healthy controls in 
2014 (Study V). 
Horses that had taken part in the first clinical study on autoserum therapy (II) were recruited 
through active advertising in the main horse magazines in Finland, while subjects in the other 
studies (I, III-V) consisted of horses whose owners or local veterinarians had contacted the author 
due to summer eczema over the years. The diagnosis was based on a clinical examination per-
formed by the author or by local veterinarians. All horses with typical clinical signs of summer 
eczema during thermal summer (mean 24-h temperature 10ºC or above) were included. Horses 
with pruritus before or after this summer season were excluded. Furthermore, horses that had been 
simultaneously medicated with antihistamines or glucocorticoids were excluded, while all other 
treatments presented in detail later (Table 3) were permitted. The additional inclusion criterion for 
eczema horses in Study V was that a matched control horse could be obtained from the same stable 
where the affected horse was kept.
    Healthy horses without a history of summer eczema were used as controls in Studies IV 
and V. In Study IV, all controls were Finnhorses and they were collected from stables that si-
multaneously housed horses suffering from summer eczema, while Study V comprised matched 
healthy controls that lived on the same farms and were fed with a similar fodder as their affected 
counterparts.
   The studies on therapy were approved by the Animal Care and Use Committee of the Uni-
versity of Helsinki (25.04.1997), and the use of healthy horses in Study V was approved by the 
Regional State Administrative Agency of Southern Finland (ESAVI/1016/04.10.07/2014). Own-
ers’ signed informed consent for inclusion was obtained. 
Data of horses
Information about the horses was acquired by questionnaire (Appendix I) and supplemented with 
interviews when necessary. For all horses, data were collected on breed, gender, age and clinical 
signs. Additionally, age at onset, duration of disease and previous treatments were recorded. Clini-
cal signs were categorized by the author as mild, moderate or severe depending on the size of skin 
lesions (Figure 3). Signs were regarded as mild if pruritus was the only clinical sign. Horses with 
pruritus and mild skin lesions in the mane, tail and/or body were classified as having moderate 
signs, while horses with pruritus and large skin lesions were graded as having severe signs. Own-
ers’ opinions about aggravating factors were also requested. 
   Information about the autoserum therapy was collected yearly in 1997-2008, and the ques-
tionnaires were sent to owners in late autumn of the year that therapy had been started (II, III). The 
mode of the questionnaire (Appendix II) was similar over the study period. However, it was not 
possible to acquire full data for all horses in Studies I and III, and thus, the total numbers of horses 
vary for the individual variables presented in the tables.    
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Figure 3. Clinical signs of summer eczema were classified as mild (a, b), moderate (c, d) or severe (e, f) depending on the severity of skin 
lesions in the mane, tail and body (I-V). 
a. b.
c. d.
e. f.
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Autoserum preparation and therapy
Horses in Studies II, III and V were treated with an autologous serum preparation that was intro-
duced in Study II. A blood sample was collected into a 10 ml plain serum tube when a horse had 
shown typical clinical signs of summer eczema for at least 2 weeks. The sample was kept at room 
temperature and sheltered from sunshine until harvesting. Serum was harvested without using a 
centrifuge when blood cells were clotted and clear serum was visible. A sample of 0.05-0.1 ml 
was taken from the superficial layer of the serum. This aliquot was washed twice by shaking with 
sterile water (1:100), and the same volume was again taken from the superficial layer of the dilu-
tion. After the second washing, the same volume was taken again from the superficial layer and the 
final dilution was made in 40-48% ethanol. Ten drops of this solution were absorbed into 20 g of 
ordinary sugar granules. These granules were stored in plastic or glass bottles at room temperature 
and sheltered from sunshine. The administered dose consisted of 10-20 sugar granules and it was 
given orally once a day for 2 weeks, followed by a 1-week pause, after which horses were treated 
again for one week. After this basic period, treatment was repeated as 1-week courses whenever 
horses showed clinical signs (II, III).
In Study II, 28 of the total of 67 horses participated in the randomized, placebo-controlled and 
double-blinded part of the study, and these horses were randomly divided into placebo and autose-
rum therapy groups. Horses in the placebo group were treated with a preparation that was made 
otherwise similarly, except that no serum was added. 
The efficacy of the autoserum therapy in the randomized, placebo-controlled and double-blinded 
part of Study II was evaluated after a 4-week treatment by the author according to the same scale 
that was used to grade the clinical signs. The treatment was regarded as beneficial when clinical 
signs became milder on this scale. After this 4-week study period, all horses in the placebo group 
were treated also with autoserum preparation. 
   Results of the horses without placebo controlling and blinding in Studies II and III were 
based on owners’ opinions of the therapy acquired by questionnaires and interviews. Their opin-
ions were expressed as none, little or considerable benefit. If the owner could not express clear 
opinion, the answer was recorded as no opinion. In addition, information about the time needed 
for possible alleviation of clinical signs, frequency of medication and any related side effects was 
acquired. Owners whose horses participated in the original placebo-controlled study (II) were 
interviewed 5 years later. Information regarding the use of autoserum preparation and their horses’ 
clinical condition over the 5-year period was collected (III).    
   Although Study V did not focus on the clinical efficacy of autoserum therapy per se, the 
same scale used in Study II was applied in Study V to assess changes in clinical signs after therapy.
Blood samplings for lipid analyses
PL contents were analysed from both autologous serum preparations (IV) and horses’ sera (V). 
In Study IV, autoserum preparations were made as introduced earlier in this text, however, the 
amount of serum used was 0.065 ml in all samples and the final dilution was made in 48% ethanol. 
Lipid analysis of autoserum preparations was performed using these final dilutions, and they were 
stored at room temperature until analysed. Sera from healthy controls were collected at the same 
time as affected horses showed clinical signs and were prepared and stored similarly.
The first blood samples for serum PL analyses (V) were drawn when eczema horses had shown 
typical clinical signs of summer eczema for at least 2 weeks, and the second samples when the 
eczema horses had been on autoserum therapy for 4 weeks. Blood samples were taken using 10 
ml plain vacuum tubes that were filled fully and kept at room temperature for at least 3 hours 
before harvesting. Sera were harvested without using centrifugation. Of the serum, 0.065 ml was 
taken from the superficial layer of the serum and added to 4.2 ml of 48% ethanol and stored at 
room temperature until analysed. Samples were collected from the matched controls similarly and 
simultaneously and also handled in the same manner.
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Phospholipid analyses
PLs were analysed from both autologous serum preparations and sera of affected and healthy 
horses. Lipid analyses were performed in the laboratory of Docent Pentti Somerharju, Department 
of Biochemistry and Developmental Biology, Faculty of Medicine, Helsinki University. Autose-
rum preparations (IV) were analysed by electrospray ionization mass spectrometry (ESI-MS) with 
direct injection into the mass spectrometer, while liquid chromatography mass spectrometry (LC-
MS) with selective reaction monitoring (SRM) was used to detect lipids in the serum (V). The 
main PL classes analysed were PC, PE, PS, PI, PA and SM. 
Lipid analysis of autoserum preparation: The samples in 48% ethanol were dried under a N2 
stream and the residue was reconstituted in 500 µl of chloroform/methanol (1:2) and stored at 
-20ºC. Half of each sample was taken for preliminary mass spectrometry analysis to ascertain the 
constitution of the lipids in it, and unlabelled external standards were added to the remainder in or-
der to quantify the amount of lipids. After addition of aqueous NH4OH (4%, i.e. 1% of NH4OH), 
the sample was infused at 6 µl/min to a Micromass Quattro Micro triple-quadrupole mass spec-
trometer (Waters, Milford, MA, USA) (Hermansson et al. 2005). Specific scans in both positive 
and negative ion modes for the detection of individual PL classes based on their head groups and 
species based on their acyl chain compositions were performed. Spectra were acquired for 5 min 
over a mass range of m/z (mass-to-charge ratio) 400-950 at a frequency of 4 scans/min. Lipid 
standards, di-22:1 PC, lysophosphatidylcholine (lysoPC) 20:0 and di-18:1 PA were each added to 
all samples to quantify the concentrations of the lipid species in these classes. The spectra obtained 
were exported to Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) and the detected 
lipids were quantified by using LIMSA software (University of Helsinki, Helsinki, Finland). 
Lipid analysis of serum: All samples stored in 48% ethanol were subjected to Folch’s method 
(Folch et al. 1957) for lipid extraction, dried under a  N2 stream , reconstituted in 500 μl of 
chloroform/methanol (1:2) and further spiked with the following labelled standards (Avanti Polar 
Lipids, Alabaster, AL, USA) corresponding to each head group: D9(di-44:2) and D9(di-40:2) for 
PC, D4(di-40:2) and D4(di-20:0) for PE, D3(di-40:2) and D3(di-44:2) for PS, D6(di-36:2) and 
D6(di-28:0) for PI and finally unlabelled 25:0-SM. LC-MS with SRM was used for the analyses. 
Waters ACQUITY Ultra Performance LC system (Waters, Milford, MA, USA) equipped with a 
Waters ACQUITY BEH C18 column (1.0 × 100 mm) was used to separate the molecular species 
using gradient elution.  Solvent A was acetonitrile/H2O (60:40) with 10 mM ammonium formate 
and 1% NH4OH, while solvent B was isopropanol/acetonitrile (90:10) containing 10 mM am-
monium formate and 1% NH4OH. The flow rate was 0.13 ml/min and the column temperature 
60°C. Solvent B was set to 40% at injection and increased linearly to 100% in 14 min, remained 
at this value for 3 min, decreased back to 40% in 1 min and then remained there until the end of 
the gradient at 20 min. The eluent was directed to the ESI source of Waters Quattro Premier triple-
quadrupole mass spectrometer (Waters, Milford, MA, USA) operated in the positive ion mode. For 
SRM transitions, proton adducts of the PC, PE, PS and PI species were selected as the precursors, 
while the product ion was either the head group (PC, SM, PI) or the diacylglycerol fragment (PE, 
PS). For quantification purposes, the SRM chromatograms were integrated and the relative con-
centrations of the individual molecular species were calculated using QuanLynx software (Waters, 
Milford, MA, USA).
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Statistical analyses
Characteristics of summer eczema (I) were evaluated by Fisher’s exact test for qualitative and 
the t test for quantitative variables. One-way analysis of variance was used to assess the relation 
between the age of onset or duration of disease and the severity of clinical signs.
   Results of autoserum therapy were analysed by Fisher’s exact test in the placebo-controlled 
study (II). Binomial test was used to compare proportions of the horses with or without benefit 
from this treatment (II, III). Changes in clinical signs before the therapy and after a 5-year follow-
up (III) were evaluated by the exact McNemar’s test in the horses that participated in the original 
placebo controlled study (II).
   Differences between PL concentrations detected from autoserum preparations of healthy and 
eczema horses were assessed by using the Mann-Whitney test due to non-parametric distribution 
of the data verified by the Shapiro-Wilk test, and the correlation between PL concentrations and 
clinical signs by using Spearman’s correlation test (IV). The Friedman test was used for pairwise 
comparisons of PL concentrations in sera between the matched groups and over time (V). The re-
lationship between the change in PL concentrations and clinical signs after therapy was evaluated 
by Spearman’s correlation test (V). 
   Analyses were performed using statistical software StatsDirect (StatsDirect Ltd., Sale, 
Cheshire, UK) and PASW Statistics 18.0 [(SPSS) IBM Corporation, Armonk, NY, USA]. Two-
sided P values <0.05 were considered significant. 
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5 .  R E S U L T S
Characteristics of summer eczema
Of the 275 horses in Study I, 139 were Finnhorses, 71 Icelandic horses, 45 ponies and 12 other 
breeds, while breed was unspecified in 8 horses. All Finnhorses were born in Finland, as were 11 
of the Icelandic horses, whereas 56 horses were imported from Iceland. The origin of 4 Icelandic 
horses remained unknown. Detailed information on affected horses and their disease is presented 
in Table 1.
Horses              Gender (%)        Age at onset                    Clinical signs (%)             Duration of disease 
  ♀       ♂  mean±sd (years)          mild      moderate      severe    mean±sd (years)
All horses
n=275  48     52           6.1±4.1         9            75               16        3.3±2.4
Finnhorses 49     51           4.6±3.6        14            75               11        3.6±2.7
n=107
Icelandic
horses  46     54                9.0±2.9         3            72               25        3.0±1.9
n=60 
imported  45     55                9.6±2.0         4            69               27        3.0±2.0
n=49
born in    
Finland  50     50           6.9±4.4         0            82               18        2.8±1.9
n=11
New Forest
ponies  53     47           4.5±3.6         0            55               45        3.7±2.5
n=15
Shetland
ponies  69     31           3.8±3.1         0            90               10        3.5±1.2
n=15
Male and female horses were equally affected, and no significant differences existed between their 
clinical symptoms. Most of the horses showed moderate clinical signs (Table 1). However, New 
Forest ponies (n=15) and imported Icelandic horses suffered significantly more often from severe 
clinical signs than Finnhorses (P=0.0082 and P=0.0183, respectively), while no significant differ-
ence was found between Finnhorses and Icelandic horses born in Finland (Table 1). Severity of 
clinical signs was not associated with age at onset (Table 2). This was uniformly observed in both 
all horses and Finnhorses. Neither was there any significant relation between the duration of the 
disease and the severity of summer eczema (Table 2).
Table 1. Characteristics of summer eczema in 275 horses in Finland between 1997 and 2007 with detailed information on four breeds 
most afflicted by summer eczema (I).
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Table 2. Age at onset and duration of summer eczema in 207 horses with different types of clinical signs (I).
                    Clinical signs
            mild     moderate       severe
Age at onset (years) 
All horses (n=207)          5.4±3.9       6.2±4.0       6.3±4.5
Finnhorses (n=107)        4.7±3.6       4.6±3.6       4.1±4.2
     
Duration of disease (years) 
All horses (n=207)          2.6±1.8       3.5±2.5       2.8±1.8
When the horses entered Study I, 81% had shown clinical signs in two consecutive summers or 
more. Most of the horses showed clinical signs from May to October. Yet, the time of onset varied; 
some horses had signs already in the spring, others not until autumn. Of the owners, 241 answered 
the question dealing with aggravating factors. Most (64%) regarded biting insects as one of the 
aggravating factors. In addition, grass fodder was recorded by 19% and sunlight by 12%, while 
22% of owners were unable to specify particular factor. 
Autoserum therapy 
The 28 horses participating in the placebo-controlled and double-blinded study had suffered from 
summer eczema for 4.3±2.5 years (mean±sd, range 1-10). Of these horses, 6 (21%) had been af-
fected with mild, 14 (50%) with moderate and 8 (29%) with severe clinical signs during the years 
before this study. Of the horses enrolled without placebo-controlling but treated with autoserum 
preparation in 1997-2008, 10% had shown mild, 76% moderate and 14% severe clinical signs 
before enrollment (III).  
   Most of the horses had been treated with various methods presented in Table 3. Special blan-
kets designed for eczema horses were not in common use when Study II started, while many of the 
horses enrolled in the later study (III) used these coveralls (Table 3). In 8 horses, the beginning of 
blanket use and autoserum therapy coincided.
Table 3. Most common treatments used in horses with equine summer eczema before treatment with autoserum. 
Horses in a placebo-controlled part of Study II are indicated as A and the other horses as B. Horses participat-
ing in Study III, but not in Study II are indicated as C.
Treatment   Number of horses (%)  
  
                                          Study II       Study II          Study III   Total
                               horses enrolled  horses enrolled           horses enrolled
                                              in 1997-98, A            in 1997-98, B             in 1999-08, C                                        
                        n=28                        n=33                          n=212                n=273
Blanket                     0   (0%)      0   (0%)     103   (49%)          103   (38%)
Glucocorticoids                 10   (34%)    11   (33%)       34   (16%)            55   (20%)
Antihistamines                    5   (18%)      2   (6%)       10   (5%)            17   (6%)
Ointments   17   (61%)    24   (73%)     133   (63%)          174   (64%)
Insecticides     8   (29%)    10   (30%)       60   (28%)            78   (29%)
No treatments                    1   (4%)      1   (3%)       21   (10%)            23   (8%)
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The overall evaluation of this autoserum treatment was based on three components: a placebo-
controlled study (II), long-term information on clinical experience acquired from questionnaires 
by owners (III) and a 5-year follow-up of horses (III) originally participating in the placebo-
controlled study (II). Results of these studies are provided in Table 4.
                                                                               Clinical signs after a 4-week treatment
    not aggravated            (milder, same)                    aggravated            
Placebo-controlled study, n=28 
         autoserum group, n=14                13                                        (8, 5)                 1
                   93%                          (57%, 36%)            7%
         placebo group, n=14  7                            (5, 2)                 7     P=0.0329
    50%                              (36%, 14%)            50% 
    benefit                        no benefit                 no opinion
Owners’ opinion of
therapy, n=300                  209 (70%)        48 (16%)                 42 (14%)       
    P<0.0001
                   95% CI 0.64-0.75
                                                       Clinical signs
    mild                         moderate or severe
5-year follow-up, n=26*                    
         before therapy  6                                           20
         5 years after                 12**                           14***   P=0.0313    
    
* 2 of the original 28 horses underwent euthanasia soon after the placebo-controlled study, one of these due to another disease and one 
due to summer eczema and another disease 
**including 5 horses without clinical signs
***including 4 horses euthanized due to summer eczema in 1998-2003
In the placebo-controlled and double-blinded study (II), horses were treated for 4 weeks, after 
which their clinical status was evaluated by the author. Signs were recorded as relieved, unchanged 
or aggravated. Of autoserum-treated horses, significantly fewer horses showed aggravated clinical 
signs (Table 4). 
   Data of new horses on autoserum therapy were collected continuously in 1997-2008 and 
the total response rate by owners to the questionnaires was 88%, corresponding to information on 
301 of the 343 horses in total. One owner had not started the therapy at all, thus only opinions of 
300 owners are listed in Table 4. Based on the information from owners, most of the horses had 
benefited from this treatment (Table 4). Some of the owners could not express clear opinion, e.g. 
if therapy has commenced in late autumn, a horse had been recently bought or the circumstances 
of the horse had simultaneously changed. According to owners’ answers, clinical signs usually 
became milder during the first 4 weeks of therapy; only 13% reported positive responses later (III). 
Table 4. Clinical efficacy of autoserum therapy (II, III).
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Accelerated healing of skin lesions without the development of new damage was an initial sign 
of alleviation reported by the owners (III). Oral administration and a single daily dosage for one-
week courses, usually twice in every summer month, were regarded as convenient to perform. No 
harmful side effects were reported during the 12-year period when data were collected. 
   Of the 28 horses that were originally grouped in the placebo-controlled study (II), 26 were 
followed for 5 years (Table 4). After 5 years, significantly fewer horses suffered from severe or 
moderate signs than before autoserum therapy (Table 4). These horses had received autoserum 
preparation mainly for two summer seasons (III), mean being 2.1±1.1 seasons (range 1-5). Some 
of the horses with mild signs (Table 4) had also been treated with locally applied ointments during 
these years. Only one horse had been medicated with glucocorticoids due to simultaneous respira-
tory signs. However, a total of 5 of the original 28 horses had been euthanized due to summer 
eczema (Table 4).  
   Of the 300 horses treated by autoserum therapy in 1997-2008 (III), 16% had received no 
benefit from this therapy according to owners’ answers (Table 4). Features of these 48 horses 
were analysed in detail (III). No significant association with breed, gender or age could be found. 
Neither were clinical results significantly linked to age at disease onset or duration of disease. Ad-
ditionally, the use of special blankets showed no significant relation to better outcome of therapy. 
Severity of clinical signs was the only feature that had a significant association with the efficacy 
of this therapy; significantly fewer horses with severe signs had benefited from the treatment than 
horses with milder signs (P=0.0245). A similar trait was also observed among the 28 horses that 
had participated in the first placebo-controlled study (II); all 5 horses that were euthanized had 
suffered from moderate or severe clinical signs before autoserum therapy (Table 4). 
Phospholipids
Serum PLs were analysed from both the autoserum preparations (IV) and the sera (V) and were 
compared between healthy control horses and horses with summer eczema.
Phospholipids in autoserum preparation
Of the PL classes (PC, PE, PS, PI, PA and SM) analysed, PC, SM, lysoPC and PA were detected 
from the preparations. Of these, PC was found most abundantly, and of the PC species, 34:0, 34:1, 
34:2, 36:0, 36:1 and 36:2 displayed the highest concentrations. In addition, traces of many other 
PC species were detected and all of the PC species are presented in Table 9. The detected SM 
species were 16:0, 18:0 and 21:0, SM 16:0 showing the most abundant concentrations. Traces 
of lysolipids (lysoPC 16:0, 18:0, 18:1 and 18:2) were also found in all samples. PA was the only 
negative-charged lipid that was detected across all samples and comprised species of 32:0 and 
34:1. Relative contents of the major PLs detected in autoserum preparations of healthy and af-
fected horses are presented in Table 5.
   Horses with summer eczema showed significantly different concentrations of PC, SM and 
PA in their autoserum preparations compared with preparations from healthy controls (Figures 4, 5 
and 6). Both PC and SM were found more abundantly in the preparations of affected than healthy 
horses (P=0.042 and P=0.0017, respectively), while concentrations of PA were significantly higher 
in healthy horses (P=0.0075). Concentrations of lysoPC did not differ between affected horses and 
controls.
   Comparisons of clinical signs and concentrations of PC, SM and PA displayed significant 
associations. Both PC and SM increased according to the severity of clinical signs (both P values 
<0.001), while concentrations of PA had a negative relationship with the severity of summer ec-
zema (P<0.001).
väikkäri_sisus_17.indd   29 28.8.2017   16.40
P h o s P h o l i P i d s  i n  e q u i n e  s u m m e r  e c z e m a  a n d  i t s  t h e r a P y
30
Table 5. Relative contents of the major phospholipids detected in autoserum preparations of horses with sum-
mer eczema (n=10) and healthy control horses (n=6). Phospholipid classes: phosphatidylcholine (PC), sphingo-
myelin (SM), phosphatidic acid (PA) (IV).
Phospholipids                                   Relative content
                                                                           mean±sd (%)
                    Eczema horses                    Healthy horses 
PC                     77.7±25.9         46.2±13.3
SM                       2.1±0.7           1.1±0.3
PA                     20.2±26.3         52.7±13.4
 
                 Phosphatidylcholine, pmol/0.5 ml 
Phosphatidylcholine, pmol/0.5 ml
Figure 4. Phosphatidylcholine (PC) concentrations in autoserum preparations. Serum sample of 65 µl derived 
from horses with summer eczema (n=10) and healthy control horses (n=6) was first diluted 1:100 in distilled 
water, mixed and from top of this dilution, another 65 µl was further treated at 1:100 dilution with distilled wa-
ter. From this, 65 µl superficial aliquot was dissolved 1:100 in 48% ethanol. Ethanol was evaporated and finally 
the residue was dissolved in 0.5 ml of chloroform/methanol for ESI-MS analysis. The concentrations of lipids 
are expressed as pmol/0.5 ml and not per original serum volume. The figure displays minimum, lower quartile, 
median, upper quartile and maximum PC levels. PC concentrations differed significantly between eczema and 
healthy horses (P=0.042) (IV).
väikkäri_sisus_17.indd   30 28.8.2017   16.40
31
P h o s P h o l i P i d s  i n  e q u i n e  s u m m e r  e c z e m a  a n d  i t s  t h e r a P y
	  
	  
Sphingomyelin, pmol/0.5 ml  
Figure 5. Sphingomyelin (SM) concentrations in autoserum preparations. Serum sample of 65 µl derived from 
horses with summer eczema (n=10) and healthy control horses (n=6) was first diluted 1:100 in distilled water, 
mixed and from top of this dilution, another 65 µl was further treated at 1:100 dilution with distilled water. From 
this, 65 µl superficial aliquot was dissolved 1:100 in 48% ethanol. Ethanol was evaporated and finally the resi-
due was dissolved in 0.5 ml of chloroform/methanol for ESI-MS analysis. The concentrations of lipids are ex-
pressed as pmol/0.5 ml and not per original serum volume. The figure displays minimum, lower quartile, me-
dian, upper quartile and maximum SM levels. SM concentrations differed significantly between eczema and 
healthy horses (P=0.0017) (IV).
Figure 6. Phosphatidic acid (PA) concentrations in autoserum preparations. Serum sample of 65 µl derived 
from horses with summer eczema (n=10) and healthy control horses (n=6) was first diluted 1:100 in distilled 
water, mixed and from top of this dilution, another 65 µl was further treated at 1:100 dilution with distilled wa-
ter. From this, 65 µl superficial aliquot was dissolved 1:100 in 48% ethanol. Ethanol was evaporated and finally 
the residue was dissolved in 0.5 ml of chloroform/methanol for ESI-MS analysis. The concentrations of lipids 
are expressed as pmol/0.5 ml and not per original serum volume. The figure displays minimum, lower quartile, 
median, upper quartile and maximum PA levels. PA concentrations differed significantly between eczema and 
healthy horses (P=0.0075) (IV).
Phosphatidic acid, pmol/0.5 ml
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Phospholipids in serum
Of the PL classes analysed, all except PS were detected in the sera of healthy and affected horses, 
although the major classes were present in differing relative contents (Table 6). In addition to those 
classes presented in Table 6, PA 36:2 and lysoPC species of 16:0, 18:0 and 18:2 were detected. PC 
was the most abundant of the PL classes found, and its total concentrations in horses with summer 
eczema and in matched healthy controls are provided in Figure 7. The major molecular species of 
PC are presented in Figure 8, and all of the detected species are listed in Table 9. The most abun-
dant species was PC 36:2, in both healthy and affected horses. The total serum concentrations of 
SM in affected horses and matched healthy controls are illustrated in Figure 9, and the detected 
SM species are presented in Figure 10. The most abundant species in all samples was SM 20:0 
(Figure 10). Total concentrations of PC and SM were significantly more abundant in healthy than 
in affected horses (Table 7), despite the higher relative content of SM in the sera of horses with 
summer eczema (Table 6). Differences in specific molecular species between healthy and affected 
horses are provided in Figures 8 and 10. Concentrations of PC and SM increased in the samples 
that were collected later in the summer, both in affected horses and in their matched controls 
(horses numbered 7-10 in Figures 8 and 10). PI and PE were found in lower relative contents than 
PC or SM (Table 6). Concentrations of these minor PLs showed no significant difference between 
healthy horses and horses with summer eczema (Table 7).
Table 6. Relative contents of the major phospholipids detected in sera of horses with summer eczema (n=10) 
and their matched healthy controls (n=10). Phospholipid classes: phosphatidylcholine (PC), sphingomyelin 
(SM), phosphatidylinositol (PI), phosphatidylethanolamine (PE) (V).
Phospholipids                                   Relative content
                                                                           mean±sd (%)
                    Eczema horses                    Healthy horses 
PC       76.0±4.8         83.3±9.8
SM       21.9±3.8         14.8±8.5
PI           1.9±1.4           1.7±1.5
PE           0.2±0.2           0.2±0.2 
Figure 7. Total serum phosphatidylcholine (PC) concentrations in horses with summer eczema and in their matched healthy controls (a) be-
fore therapy and (b) after a 4-week autoserum therapy of the eczema horses. A horse and its matched control are presented consecutively. 
Serum sample of 65 μl was first diluted in 4.2 ml of 48% ethanol, which was evaporated and finally the residue was dissolved in 0.5 ml of 
chloroform/methanol for LC-MS lipid analysis. Lipid concentrations are expressed as pmol/0.5 ml and not per original serum volume. Sta-
tistical comparisons between the groups at both time points are presented in Table 7 (V).
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Figure 8. Concentrations of major species of phosphatidylcholine (PC) detected in sera of horses with summer eczema (n=10) and their 
matched healthy controls (n=10, matched pairs numbered similarly from 1 to 10) (a) before and (b) after a 4-week autoserum therapy of the 
affected horses. Samples were treated and concentrations of species are expressed as presented in Figure 7. All species showed significantly 
lower concentrations in affected horses before therapy (P<0.0001). After therapy, concentrations of PC 34:1 and PC 36:1 were significantly 
lower in affected horses, while PC 40:8 was significantly lower in healthy controls (P<0.05) (V).
Figure 9. Total serum sphingomyelin (SM) concentrations in horses with summer eczema and in their matched healthy controls (a) before 
therapy and (b) after a 4-week autoserum therapy of the eczema horses. A horse and its matched control are presented consecutively. Serum 
sample of 65 μl was first diluted in 4.2 ml of 48% ethanol, which was evaporated and finally the residue was dissolved in 0.5 ml of chloro-
form/methanol for LC-MS lipid analysis. Lipid concentrations are expressed as pmol/0.5 ml and not per original serum volume. Statistical 
comparisons between the groups at both time points are presented in Table 7 (V).
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Figure 10. Concentrations of sphingomyelin (SM) species detected in sera of horses with summer eczema (n=10) and their matched healthy 
controls (n=10, matched pairs numbered similarly from 1 to 10) (a) before and (b) after a 4-week autoserum therapy of the affected horses. 
Samples were treated as presented in Figure 9. Concentrations of species are expressed as nmol/0.5 ml and not per original serum volume. 
SM 15:0 and SM 24:1 showed significantly lower concentrations in affected horses before and SM 18:0 and SM 21:0 after therapy than in 
their healthy controls (P<0.05) (V).
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Table 7. Statistical pairwise analyses, according to the Friedman test, of differences in serum concentrations of 
the major phospholipid classes detected between horses with summer eczema (n=10) and their matched healthy 
controls (n=10, controls indicated with c). The samples collected before therapy of horses with summer eczema 
are indicated with 0 in both horses with summer eczema and their matched healthy controls, and the samples 
collected when the horses with summer eczema have been on autoserum therapy for 4 weeks are indicated with 
4 in both horses with summer eczema and their matched healthy controls. Phospholipid classes: phosphatidyl-
choline (PC), sphingomyelin (SM), phosphatidylinositol (PI), phosphatidylethanolamine (PE) (V).
  PC 0  PC 4  PC 0 c  PC 4 c
PC 0    p=0.0007  p<0.0001  p<0.0001
PC 4  p=0.0007    ns  ns
PC 0 c  p<0.0001  ns    ns
PC 4 c  p<0.0001  ns  ns 
    
  SM 0  SM 4  SM 0 c  SM 4 c
SM 0    ns  p=0.0115  ns
SM 4  ns    p=0.0005  ns
SM 0 c  p=0.0115  p=0.0005    p=0.0186
SM 4 c  ns  ns  p=0.0186 
    
  PI 0  PI 4  PI 0 c  PI 4 c
PI 0    ns  ns  ns
PI 4  ns    ns  ns
PI 0 c  ns  ns    ns
PI 4 c  ns  ns  ns 
    
  PE 0  PE 4  PE 0 c  PE 4 c
PE 0    p=0.0058  ns  p<0.0001
PE 4  p=0.0058    ns  ns
PE 0 c  ns  ns    p=0.0018
PE 4 c  p<0.0001  ns  p=0.0018 
Changes in phospholipids after therapy 
After a 4-week autoserum therapy, sera of affected horses and their matched healthy controls were 
analysed again and the relative contents of the main PL classes detected are provided in Table 
8. In healthy horses, relative contents of the PL classes remained virtually unchanged, while in 
affected horses, concentrations of PC and SM had changed, and the resulting relative contents 
hardly differed from the values of healthy horses (Table 8). No significant differences could be 
found in the total concentrations of PC or SM between healthy and affected horses after therapy 
(Table 7, Figures 7 and 9). In the horses with summer eczema, the total PC concentration had 
increased significantly (Table 7), whereas healthy horses showed a slightly decreased total con-
centration (Figure 7). Concentrations of all the major PC molecular species in the affected horses 
shown in Figure 8 increased significantly (P<0.05) after therapy, while in the healthy horses the 
only significant change found was a decrease of PC 40:8 (P=0.0007). The total concentrations of 
SM decreased in both groups (Figure 9), and this change was significant in healthy horses (Table 
7). Of the specific molecular species, concentrations of SM 16:0, 18:0, 24:0 and 24:1 decreased 
significantly (P<0.05) in both healthy and affected horses during the 4 weeks (Figure 10). Concen-
trations of PI or PE showed no significant differences between healthy and affected horses after 
therapy (Table 7).  
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Table 8. Relative contents of the major phospholipids detected in sera of horses with summer eczema (n=10) 
and matched healthy control horses (n=10) after the affected horses have been on autoserum therapy for 4 
weeks. Phospholipid classes: phosphatidylcholine (PC), sphingomyelin (SM), phosphatidylinositol (PI), phos-
phatidylethanolamine (PE) (V).
Phospholipids                                   Relative content
                                                                           mean±sd (%)
                    Eczema horses                    Healthy horses 
PC       87.4±1.7         85.6±2.7
SM       11.0±1.6         12.4±1.9
PI           1.4±0.7           1.8±1.3
PE                        0.2±0.2           0.2±0.2
Changes in phospholipid concentrations and associations with clinical signs
Alterations in PL concentrations were evaluated in 10 eczema horses according to amelioration 
or aggravation of clinical signs after autoserum therapy (V). Five of the horses had mild and 5 
moderate signs before autoserum therapy. After a 4-week therapy, clinical signs became milder in 
6 horses and remained unchanged in 3, whereas one horse suffered from an aggravated disease. 
Horses with positive clinical outcome displayed a milder decrease in the total SM concentrations 
than horses with poorer response or controls (Figure 11). The change in these concentrations 
correlated significantly with alterations in clinical status (P=0.0047). Of the specific molecular 
species, SM 15:0 showed a significant association with the change of clinical signs (P=0.0268), 
and actually, SM 15:0 exhibited also a significantly lower concentration in affected horses before 
therapy than in healthy horses, but not afterwards (Figure 10). 
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          Change in SM concentration, pmol in total of 0.5 ml    
Figure 11. Change in SM concentrations after a 4-week autoserum therapy of horses with summer eczema. A) 
Affected horses with positive clinical response (n=6) and B) without positive clinical response (n=4) and their 
matched healthy controls, Ac and Bc, respectively. Changes in concentrations are calculated from the values 
presented in Figure 9 (a and b) and are expressed as pmol in total of 0.5 ml. The figure displays minimum, low-
er quartile, median, upper quartile and maximum values of SM changes (V).
Differences in phospholipid profiles between serum and autoserum preparations
The main PLs that differed in both the serum (V) and autoserum preparations (IV) between healthy 
horses and horses with summer eczema were PC and SM. Healthy horses showed significantly 
more abundant concentrations of PC and SM in their sera (V), while in autoserum preparations 
concentrations of these PLs were significantly lower in healthy horses than in affected horses 
(IV). Specific molecular species of PC and SM detected in the sera and concentrated in autoserum 
preparations are provided in Table 9. Autoserum preparations contained more species of PC than 
present in serum. Most of these species in the autoserum preparations seemed to have two double 
bonds or fewer; this was especially evident in the species with shorter acyl chains (Table 9). Ac-
cordingly, in autoserum preparations those species with more double bonds were found only in 
species with long acyl chains such as 38:5, 40:5 or 40:6 (IV). In addition, these highly unsaturated 
species were detected in minor quantities, while in serum (V) they were also found in abundant 
concentrations, e.g. 36:4 or 40:8 (Figure 8). In contrast to PC, more molecular species of SM were 
detected in serum than in autoserum preparations (Table 9). In serum, SM 20:0 was the most abun-
dant in all horses (V), whereas SM 16:0 prevailed in autoserum preparations (IV).
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            PC
Sera                      Autoserum preparations                 Same species in both
26:0, 28:0, 31:1, 33:1, 33:2,       28:0, 30:0, 30:1, 31:0, 31:1, 28:0, 31:1, 33:1, 33:2, 33:3
33:3, 34:1, 34:2, 36:1, 36:2,       32:0, 32:1, 33:0, 33:1, 33:2           34:1, 34:2, 36:1, 36:2, 36:3,
36:3, 36:4, 36:6, 38:8, 40:8        33:3, 34:0, 34:1, 34:2, 34:3,             36:4  
                35:0, 35:1, 35:2, 35:3, 36:0, 
                      36:1, 36:2, 36:3, 36:4, 37:0,
                      37:1, 37:2, 38:0, 38:1, 38:2,
                      38:3, 38:4, 38:5, 39:0, 40:0,
                      40:1, 40:2, 40:4, 40:5, 40:6 
                          SM
Sera                        Autoserum preparations                 Same species in both
15:0, 16:0, 18:0, 20:0, 21:0,               16:0, 18:0, 21:0                 16:0, 18:0, 21:0
24:0, 24:1
Table 9. Phosphatidylcholine (PC) and sphingomyelin (SM) species detected in sera (n=20), autoserum prepa-
rations (n=16) or both in healthy horses and horses with summer eczema (IV, V).
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6 .  D I S C U S S I O N
General aspects of equine summer eczema
According to this thesis, Finnhorses and Icelandic horses were the breeds most afflicted by equine 
summer eczema in Finland, the vast majority of horses comprising Finnhorses (I, III). During the 
11-year period of Study I the average number of Finnhorses in Finland was 19 500 and the number 
of Icelandic horses 1300, while the total number of other breeds was continuously about 10 000 
greater than the number of Finnhorses over those years (Hippos 2016). Noteworthy is that only 
23% of the eczema horses in Study I comprised breeds other than Finnhorses or Icelandic horses, 
while in many countries this disorder is typical in warmblood horses (Kurotaki et al. 1994, Stein-
man et al. 2003a).
   Icelandic horses imported from Iceland are known to be prone to insect hypersensitivity 
since they have not been predisposed to bites of Culicoides (Broström et al. 1987, Björnsdottir et 
al. 2006), indicating that horses exposed since birth are less commonly affected than horses with-
out early contacts with insects (Broström et al. 1987, Björnsdottir et al. 2006). In Finland, virtually 
all horses, even in northern Finland, are exposed to biting insects since birth, and thus, unknown 
factors are responsible for the susceptibility of Finnhorses to develop summer eczema. Andersson 
et al. (2012) suggested that in horses not born versus born in Iceland genetic susceptibility may 
play a more marked role in the outbreak than purely environmental factors. However, genetic stud-
ies on Finnhorses have not yet been performed. Due to strict official breeding orders and accurate 
records maintained for Finnhorses for over a century, this breed could be an interesting target for 
such studies, as has been shown in the recent study on crib-biting in Finnhorses (Hemmann 2014). 
   Study I revealed that summer eczema usually manifests by the age of 5 years and seldom 
after 12 years in Finnhorses. It is therefore a disease of young animals, although it tends to fol-
low a horse for years (Barbet 1992). Findings of the typical age of onset in other breeds are 
controversial since in some studies summer eczema has been concentrated in grazing seasons and 
in others the prevalence of the disease has been compared between age groups (Broström et al. 
1987, Halldorsdottir & Larsen 1991, Steinman et al. 2003a). However, Icelandic horses not born 
in Iceland were found to develop summer eczema by the age of 5 years (Halldorsdottir & Larsen 
1991, Schurink et al. 2013), which is consistent with the findings in Finnhorses. Interestingly, 
Wagner et al. (2003) demonstrated that Icelandic horse foals younger than six months did not 
show any serum IgE when they were exposed to biting insects, in contrast to their simultaneously 
IBH-affected or healthy dams. Furthermore, in atopic dermatitis of humans, 85% of the outbreaks 
are found before the age of 5 years, but rarely after adolescence (Kawakami et al. 2009, Dubrac et 
al. 2010, Rutkowski et al. 2014). This implies that there may be some common immune-mediated 
mechanisms that predispose to allergies or atopic disorders in youth. Notably, age at onset seemed 
not to predict severity of clinical signs neither in all horses nor in Finnhorses (I).
   Most of the horses participating in this study had moderate clinical signs, and this was also 
the case among Finnhorses (I, III, IV). The subgroups of horses that significantly more often 
showed severe signs than Finnhorses were New Forest ponies and Icelandic horses imported from 
Iceland (I). The latter finding agrees with the observation that imported Icelandic horses show 
more severe disease than horses not born in Iceland (Broström et al. 1987). Despite the seasonally 
typical recurrences, clinical signs seemed not to be aggravated over the years, with no significant 
difference found between duration of the disease in horses with mild, moderate and severe signs 
(I). This result differs from an earlier cross-sectional survey on Icelandic horses (Broström et al. 
1987) in which clinical signs tended to worsen with time, but is in accordance with the later find-
ings of Schurink et al. (2012, 2013), who showed no increase in severity over the years. 
   The rather small number of horses with mild signs may be partly explained by the strict limits 
in classification of signs and perhaps owners’ unwillingness to contact veterinarians when their 
horses suffered only from pruritus without skin lesions, i.e. mild disease (I, II, III). This is sup-
ported by the data of van Grevenhof et al. (2007) showing that Shetland ponies suffer more often 
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from mild than severe signs when mild signs also include signs of dermatitis. In the present study, 
there were no Shetland ponies with only pruritus without skin lesions (I). Thus, accurate classifica-
tion of clinical signs when results between various clinical studies are evaluated is critical.
Autoserum therapy
The idea to use autoserum therapy in the treatment of equine summer eczema stemmed from 
our earlier studies on equine sarcoid and its treatment with an autogenous polymerized tumour 
vaccine prepared from excised sarcoid material and supplemented with serum proteins (Tallberg 
et al. 1979, Kinnunen et al. 1999, Hallamaa 2007). However, in summer eczema our original 
hypothesis focused on lipids that were supposed to be excessively produced and thereby released 
into the circulation, leading to abnormal aggregate complexes of lipid particles (II). According to 
this hypothesis, these clusters would be incapable of binding their corresponding receptors on the 
plasma membrane, thus preventing the target signalling pathways. Additionally, lipids as a part of 
floating lipoproteins (Watson et al. 1991, 1993, Hammad et al. 2012) constitute the main fraction 
that could manage the serial dilutions with water and finally with highly concentrated ethanol 
during the processing of serum since water-soluble molecules are dissolved during washings and 
more insoluble molecules, such as proteins, will be denatured by alcohol (Nelson & Cox 2008).
   The results of the first placebo-controlled and double-blinded clinical study on this therapy 
were encouraging (II). Horses in the placebo group showed significant aggravation during the 
4-week follow-up compared with horses on autoserum therapy (II). In general, it is important to 
explicitly state the criteria for the evaluation of clinical results, especially between the different 
studies and therapies. In the present study, horses were assessed according to the same 3-graded 
scale over the entire study period from 1997 to 2014. Based on the long-term information col-
lected about the disease and autoserum therapy (I, II, III and V), this scale proved to be a practical 
and sufficient method for classifying clinical signs and evaluating therapeutic responses, espe-
cially in Finnhorses (I).
   The majority of the horses treated by autoserum therapy (III) had suffered from moderate or 
severe clinical signs before enrolling. Interestingly, horses entering this study after 1998 showed 
significantly less severe signs than horses included earlier (III). The use of special blankets had 
simultaneously become more common in Finland (III), which could explain this difference since 
there were no blanket users when the first placebo-controlled study was carried out. However, no 
significant difference in the clinical response to autoserum therapy was found between horses with 
and without a blanket (III). These special blankets may shield horses from developing large skin 
lesions, although this relationship was not statistically assessed here. In any case, the beneficial 
effect of the use of a blanket combined with overnight stabling has been demonstrated by Olsén 
et al. (2011). 
   After a 5-year follow-up, significantly fewer horses showed moderate or severe signs than 
before treatment and some of the horses were actually symptom-free (III). According to earlier 
research, equine summer eczema does not typically improve with age (Scott & Miller 2003, Schaf-
fartzik et al. 2012), although Schurink et al. (2009) did report unexpectedly low repeatability 
among a Shetland mare population. However, they speculated that these results were probably 
due to ambiguity in data collection (Schurink et al. 2009), and in their later studies this trait of 
low repeatability could not be demonstrated (Schurink et al. 2012, 2013). Therefore, this follow-
up result of amelioration in 12 horses was a favourable outcome, especially as most of the horses 
had been affected with summer eczema for several years before enrolment. However, 5 horses of 
the original 28 horses had been euthanized due to severe clinical signs of summer eczema, which 
had not improved with autoserum therapy (III). When horses without benefit from this therapy 
were assessed in detail, severity of initial clinical signs had a significant association with failure 
of autoserum treatment (III). This is consistent with earlier studies on allergen-specific immuno-
therapy in both horses and humans; poorer responses were found in the treatment of disorders 
with more severe signs (Anderson et al. 1996, Ginsberg & Eichenfield 2016, Slavyanakaya et al. 
2016). It has been demonstrated recently that various cell surface proteins, especially those linked 
to eosinophils, were expressed differently depending on the type and severity of allergic disorders 
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(Metcalfe et al. 2016). Some of those proteins were up-regulated when patients showed mild 
or moderate signs, whereas others only in severe clinical manifestations (Metcalfe et al. 2016). 
Therefore, unknown immunological/biochemical factors may be related to the extent of equine 
summer eczema, rendering the most affected horses refractory to therapies, including autoserum 
treatment. 
   Owners’ opinions of the therapy were mainly positive. Approximately 70% of horses had 
benefited from this autoserum treatment according to their owners (III). However, the lack of 
placebo-controlling makes the assessment of this result somewhat unreliable. Owners may evalu-
ate findings without reasonable objectivity or may be willing to give positive answers to please 
the researcher. Nevertheless, most owners in this study had been involved with this disorder for 
years, thus being experienced and fairly sceptical of various treatments. In addition, responses of 
owners who had recently purchased their horses and were unfamiliar with the manifestation of the 
disease were recorded as ‘no opinion’ by the author. The rather high proportion of horses receiving 
considerable benefit from this treatment, about 28%, relative to horses receiving some or no ben-
efit, 42% and 16%, respectively (III), suggests that most of the positive answers by owners were 
based on realistic evaluations. Interestingly, in most of the horses receiving benefit from therapy, 
clinical signs started to regress within 2-4 weeks of commencing autoserum therapy (III), a time 
when allergen-induced late cutaneous responses have been observed to be suppressed in humans 
after allergen-specific immunotherapy (Matsuoka et al. 2013). 
   The long-term study made it possible to attenuate the impact of annual weather conditions 
on clinical results since various climatic changes influence the amount of Culicoides (Björnsdottir 
et al. 2006, van Grevenhof et al. 2007). Furthermore, over the years of this study, horses were en-
rolled from many areas of Finland, thus minimizing the potential impact of geographical variation 
(Broström et al. 1987), such as seaside (Riek 1953), altitude (Steinman et al. 2003a) or vegetation 
(van Grevenhof et al. 2007), on the number of insects. 
   In general, oral administration was regarded as easy to perform, and no adverse effects 
related to this therapy were recorded during the series of studies carried out in 1997-2014. The 
route of administration plays an important role in compliance, especially when we are working 
with animals. Oral administration is considered more convenient than, for instance, serial injec-
tions (Anderson et al. 1996, Valenta et al. 2012, Jonsdottir et al. 2015, Slavyanakaya et al. 2016). 
One disadvantage of autoserum therapy, besides the poor clinical outcome in some horses, was the 
2-week wait period before the blood sample for autoserum preparation could be collected. This 
delay was especially stressful when a horse showed severe signs soon after onset. However, this 
time was needed since the prerequisite for blood sampling (II, III, V) was that the allergic reaction 
be fully initiated, which occurs within 2 weeks of exposure to insect bites (Barbet 1992).  None-
theless, autoserum therapy was continued the following summer, when necessary, with the former 
preparation stored at room temperature, without renewed collection of blood (III).
Phospholipids
Findings in serum
Of the major PLs in the mammalian serum (Fuchs et al. 2009, Quehenberger & Dennis 2011), 
PC and SM were detected in healthy and affected horses. However, horses with summer eczema 
showed significantly lower total concentrations of PC and SM in their sera than healthy con-
trols (V). Due to matching of these horses, environmental circumstances, such as the fodder and 
feeding regimen, were similar between the affected horses and their counterparts. Moreover, the 
samples from the affected horse and its matched healthy control were collected at the same time. 
Therefore, it is unlikely that nutritional factors had markedly impacted on these results, although 
the composition of serum lipids (Subbaiah & Liu 1996, Vesper et al. 1999, O’Connor et al. 2007, 
Fuchs et al. 2009, Paassilta et al. 2014) and even of milk lipids (Laitinen et al. 2006, Thijs et al. 
2011, Kuhnt et al. 2015) is strongly dependent on the type of diet, and certain diets may per se de-
crease the risk for allergies (Magnusson et al. 2015). It has been suggested that PC is consumed as 
a source of arachidonic acid that is further converted to leukotrienes in cells assembling in allergic 
responses (Metcalfe et al. 2016). Thus, the lower PC levels in the serum of eczema horses could 
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be explained by the accelerated turnover to eicosanoids. Also concentrations of SM may fluctu-
ate according to the amounts of PC since SM can be converted from PC (Olivera & Rivera 2011, 
Ried et al. 2013), and these PLs are carried by the same lipoproteins in the circulation (Watson 
et al. 1991). Furthermore, SM may be consumed via sphingomyelinase action in the synthesis of 
ceramide, which is the main component of the epidermal lipid barrier (Proksch et al. 2003, Kolter 
2011). This barrier needs constant repairing in severe skin afflictions (Proksch et al. 2003). Affect-
ed horses in Study V did not show large skin lesions, and therefore, the lower SM levels in these 
horses were probably not linked to skin injuries. In addition, epidermal lipid synthesis is highly 
independent of circulating lipids (Proksch et al. 2003). It seems more likely that the decreased SM 
concentrations reflect immune-mediated changes in lipid metabolism and mediators since SM is a 
precursor for signalling molecules such as S1P (Olivera & Rivera 2011, Maceyka & Spiegel 2014, 
Kulinski et al. 2015). However, concentrations of S1P were not analysed in this thesis, and the role 
of these molecules remains to be elucidated. 
   Leslie et al. (2008) demonstrated that serum lipids of healthy humans, especially polar lipids 
such as PLs, regulate expression of CD1 molecules on the APCs, i.e. lipids regulate presentation 
of lipid antigens, and thereby, the subsequent T cell activation. These serum lipids act in a dose-
dependent manner and this action is reversible depending on the state of inflammatory responses 
(Leslie et al. 2008). Horses may also have lipid antigens involved in the pathogenesis of summer 
eczema. However, lipid antigens and the adjacent CD1 antigen-presenting proteins related to sum-
mer eczema have not been demonstrated thus far, although the role of lipids as a primary or at least 
a part of protein antigens has been widely recognized in allergies affecting humans (De Libero 
& Mori 2010, Jyonouchi et al. 2011, Bublin et al. 2014, Layre et al. 2014). The findings of Study 
V suggest that the lower levels of PC and/or SM in eczema horses compared with healthy horses 
could predispose these horses to continued antigen presentation, and further, when these concen-
trations have become restored to levels indistinguishable from healthy horses, also clinical signs 
have become milder (V). The observations of Leslie et al. (2008) seem to support this speculation.
   PA was detected in serum (V), which was a surprising finding. This PL has not been dem-
onstrated earlier in horse serum (Fuchs et al. 2009), and as a minor inner leaflet lipid it is not a 
usual component of serum (Nelson & Cox 2008, Fuchs et al. 2009). In the present study, sera 
were harvested without centrifugation; it is thus probable that the samples contained also a few 
blood cells, leading to these detectable amounts of PA (IV, V). This is also supported by the fact 
that healthy horses had PA more abundantly in their autoserum preparations than affected horses 
(IV). The erythrocyte sedimentation rate is generally slower in healthy horses than in horses with 
inflammatory disorders since fibrinogen increases aggregation of red blood cells (Baskurt et al. 
1997), leading to more rapid sedimentation in horses with inflammation. Despite the significant 
differences in PA detected in autoserum preparations of healthy and affected horses, PA may not 
have a marked role among the PLs related to this disease. In addition to PA, lysoPC was detected 
in serum (V). This PL mainly originates from PC after phospholipase degradation during storage 
at room temperature (Breier et al. 2014) and was thus an expected finding. Therefore, the impact 
of lysoPC was not evaluated further, especially when its concentrations did not differ significantly 
between healthy and affected horses (IV, V). Interestingly, in humans with cholestasis induced 
pruritus, serum concentrations of lysoPA and autotaxin activity were significantly higher than in 
healthy controls (Oude Elferink et al. 2011). Autotaxin is an enzyme that converts lysoPC into 
lysoPA, which in turn has receptors on neurons and is thus suggested to be involved in itch signal-
ling (Oude Elferink et al. 2011). 
   Of the PL classes analysed, only PS was not detected in serum samples (V). This PL has been 
demonstrated in EVs (Laulagnier et al. 2004, Chaput & Théry 2011), particularly at the surface of 
exosomes, which are EVs of endosomal origin (Raposo & Stoorvogel 2013). Extracellular vesi-
cles are small, 50-100 nm, membrane-coated particles (Harding et al. 2013, Raposo & Stoorvogel 
2013) that are secreted by numerous cell types, especially cells involved in immune responses 
(Bobrie et al. 2011, Chaput & Théry 2011). Although PS was not detectable in the samples, this 
does not necessarily rule out the possibility that some part of the detected PLs had stemmed from 
exosomes present in the circulation. The amount of the analysed serum from these horses was 
small (V) and consequently also the possible number of vesicles included. Additionally, PC, SM 
and PE have been demonstrated to show higher relative contents of the PLs usually detected in 
those vesicles compared with the levels of PS (Laulagnier et al. 2004). 
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Findings in autoserum preparations in comparison with serum   
The presence of lipids in autoserum preparations was the original hypothesis for the treatment 
of horses with summer eczema in Studies II and IV. Additionally, the finding that affected horses 
showed more abundant concentrations of PC and SM in these preparations (IV) was in accordance 
with our preliminary suggestion that horses with summer eczema have abnormally large amounts 
of lipids in the circulation (II). Therefore, there was a discrepancy between the results from serum 
and autoserum preparations. In contrast to our preliminary hypothesis (II), affected horses showed 
significantly lower concentrations of these major serum PLs in their sera than healthy horses (V). 
This contradictory finding may be related to the changes in hydrophobic/hydrophilic interactions 
between lipid molecules and their lipoprotein carriers (Watson et al. 1993) among horses with 
summer eczema. Lipid composition of autoserum preparations showed that hydrophobic lipid 
classes and their specific species had been concentrated in those preparations (IV). Although mi-
nor amounts of PI and PE were detected in serum (V), they were not found in the preparations 
(IV). Evidently, this resulted not only from their usually low relative content in mammalian sera 
(Fuchs et al. 2009), but also from their more hydrophilic nature compared with PC or SM (Nelson 
& Cox 2008). In autoserum preparations, the less water-soluble PC species were prevalent and the 
most hydrophilic species were found only in low concentrations (IV), whereas in the serum these 
more water-soluble species were abundantly present (V). This supports the interpretation that the 
most hydrophilic species were dissolved in water during the processing of serum. However, spe-
cies of SM seemed to act in a slightly different way. SM 16:0 was the most abundant in autoserum 
preparations, while SM 20:0 predominated in serum, although the former should be more soluble 
in water than the latter (Nelson & Cox 2008). This suggests that there are at present some obscure 
factors influencing hydrophobic/hydrophilic properties of certain PLs and their specific species in 
horses with summer eczema. Mineral salt interactions have been found to affect the solubility of 
lipids and make lipids even more insoluble in water (Folch et al. 1957). Moreover, lipid-mineral 
salt interactions dissociate, but only after several washings (Folch et al. 1957). This could be a 
potential explanation for eczema horses having lower concentrations of PC and SM in serum but 
higher concentrations in autoserum preparations than healthy horses, and for certain more water-
soluble species being concentrated in autoserum preparations.
Phospholipids and clinical status 
In horses with summer eczema, serum concentrations of PC and SM were significantly lower than 
in healthy control horses, although they per se showed no significant associations with the severity 
of clinical signs before therapy (V). On the other hand, concentrations of PC and SM in autoserum 
preparations displayed a significant relation to severity of signs (IV). Based on these findings, PL 
profiles in serum seemed to reflect “a rough picture” of the clinical status, i.e. healthy or affected, 
while in autoserum preparations they provided a more detailed fingerprint. This implies that lipid 
particles linked to the severity of this allergic disorder could have been concentrated in autoserum 
preparations. However, this interpretation requires further studies with a greater number of horses 
than here.
   Changes in the total SM concentrations correlated significantly with the alterations in clinical 
status in response to therapy (V). Of the specific SM species, SM 15:0 showed a significant as-
sociation with the alterations in clinical signs after therapy and also was exhibited at significantly 
lower levels in eczema horse sera than healthy horse sera before therapy, but not afterwards. 
Therefore, SM seems to play a dynamic role in the course of this disease.
Mode of action in autoserum therapy 
The underlying mechanism of this therapy remains unknown. A rational explanation for the ac-
tion is probably related to cell signalling pathways. The small amounts of various PLs, detected 
mainly in pico- or nanomolar concentrations, in the autoserum preparations could be sufficient 
only as a part of signalling cascades, particularly participating in downstream pathways. On signal 
transduction, minute amounts of molecules are able to interact not only as inducers but also as 
amplifiers of the corresponding cascades (Nelson & Cox 2008, van Meer & de Kroon 2011). Na-
nomolar concentrations are typical for lipid mediators, with these substances being formed during 
inflammation and its resolution (Serhan & Petasis 2011, Stables & Gilroy 2011); S1P receptors, 
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for instance, are sensitive to nanomolar affinities (Chun et al. 2010). Sometimes, higher amounts 
of lipid mediators even decrease the expression of target substances, while lower concentrations 
accelerate their production (Demetz et al. 2014). Intriguingly, sphingolipids have been detected 
in other biological substances, e.g. dairy products such as milk and butter, usually in micromolar 
concentrations (Vesper et al. 1999). 
   The site of action and the target cells involved could not be established based on the infor-
mation here. However, some cautious suggestions can be made. In autoserum preparations, lipid 
particles were absorbed into sugar granules for oral administration. Recently, it has been demon-
strated that taste receptors are able to regulate innate immune defences and these taste receptors 
are also expressed in various tissues beyond the oral cavity, thus supporting their additional func-
tion in immune responses (Laffitte et al. 2014, Lee & Cohen 2015, Workman et al. 2015). Of these 
receptors, bitter and sweet taste receptors are the most important (Lee & Cohen 2015, Workman 
et al. 2015). Therefore, it seems possible that sweet taste receptors could perceive lipid molecules 
embedded in sugar granules and provide the primary step for the ongoing action. In the next 
phase, immune cells, probable basophils, might interact with taste receptors, potentially leading 
to a modification of FcεRI receptors. Mast cells and basophils are the main cell types assembling 
in allergic reactions by releasing histamine and a plethora of lipid mediators and cytokines when 
activated via FcεRI receptors (Kawakami & Galli 2002, Wagner et al. 2006, Kawakami et al. 
2009, Cromheecke et al. 2014, Galli et al. 2016, Metcalfe et al. 2016). However, of these cells 
only basophils are detected in the circulation (Galli et al. 2016, Kratzer & Pickl 2016, Metcalfe et 
al. 2016). Basophils have been implicated as one of the major cell populations expressing IgE in 
the peripheral blood of IBH-affected horses (Wagner et al. 2003) and cell response to specific al-
lergen challenge in horses with summer eczema (Langner et al. 2008). Therefore, basophils could 
be one of the messengers participating in the response during autoserum therapy. This suggestion 
is based also on the following investigations dealing with basophils and allergic inflammation. Lo-
cal antigen challenge has been shown to activate circulating basophils, i.e. inducing also systemic 
allergic influence (Saini et al. 2004). In addition, basophils are able to promote CD4+ T helper 
cell polarization (Sokol et al. 2008, Kim et al. 2009, Otsuka & Kabashima 2015) and also to act as 
antigen-presenting cells to CD8+ T cells (Kim et al. 2009). Moreover, Mukai et al. (2005) demon-
strated that basophils are essential for the development of IgE-mediated chronic allergic reactions 
without the intervention of T cells or mast cells. Recently, basophils have been linked to the devel-
opment of severe cutaneous hypersensitivity to mosquito bites in humans (Sakakibara et al. 2015). 
Because basophils interact in various phases of immune responses and they possess capacities not 
only in innate immune responses but also in adaptive immune responses (Schneider et al. 2010), 
they might be involved in the course of summer eczema and its resolution after autoserum therapy. 
Further basic research, including cell culture approaches, is needed. 
   In mast cells, ensuing activation of FcεRI receptors promotes synthesis of S1P (Olivera 
& Rivera 2005, 2011, Price et al. 2008, Kulinski et al. 2015), and this lipid mediator has certain 
two-dimensional functions by enhancing or suppressing allergic responses, possibly depending 
on type of allergen and site of action (Kulinski et al. 2015). An interesting finding was made in 
the study of Hamza et al. (2008); a supernatant collected from cultured PBMCs of healthy horses 
and added to cultures from horses with summer eczema abrogated IL-4 production in these cell 
cultures. They observed that IL-10 and TGF-β, the major cytokines produced by Treg cells (Ak-
dis et al. 2005), possessed this down-regulating effect on IL-4 secretion when these cytokines 
were simultaneously expressed. But, as stated by Hamza et al. (2008), there may be other factors 
present in the supernatant that also promote or affect IL-4 down-regulation. Notably, they added 
autologous serum to these cell cultures, and accordingly, the supernatants probably contained 
signalling molecules, such as S1P, that are normally present in serum (Christoffersen et al. 2011, 
Hammad et al. 2012). Afterwards, Hamza et al. (2012) showed that horses with summer eczema 
were incapable in response allergen challenge of promoting expression of Treg cells, in contrast 
to healthy horses. Intriguingly, S1P plays a pivotal role in the maturation and function of Treg 
cells (Cyster & Schwab 2012). Galli et al. (2016) demonstrated that serum collected from animals 
exposed to honey bee venom prevented detrimental allergic reactions in naive animals, although 
injected in minute amounts. When binding to the FcεRI receptor was blocked, the beneficial ef-
fect of the donor serum disappeared (Galli et al. 2016). This cautiously supports the speculation 
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that the autoserum preparation could interpose via FcεRI receptors and the changes found in the 
SM concentrations of the horses with summer eczema may reflect or influence alterations in S1P 
production. The findings of significantly higher SM concentrations in the preparations of affected 
horses than in healthy horses and the significant correlation between the changed SM concentra-
tions and clinical status after therapy are in agreement with this assumption. However, S1P was 
not analysed in this thesis. Even though alterations in SM concentrations correlated with clinical 
signs, no conclusions can be drawn from the causality. 
   Although many research projects associated with S1P signalling are ongoing (Chun et al. 
2010), various basic mechanisms between lipid mediators and allergic responses are still unre-
solved, not only in relation to the present thesis, but also at a more general level (Christoffersen et 
al. 2011, Cyster & Schwab 2012, Maceyka & Spiegel 2014, Kulinski et al. 2015, Galli et al. 2016). 
Advanced methods to analyse detailed information on cell biochemistry (Shaner et al. 2009, Ham-
mad et al. 2010, Harkewic & Dennis 2011, Ried et al. 2013, Maceyka & Spiegel 2014, Metcalfe 
et al. 2016) will help to illuminate the answers.
Limitations of the thesis
In addition to the limitations related to autoserum therapy and discussed earlier in that section, 
there are limitations in the analysis of the blood samples. By low speed centrifugation for autose-
rum preparation, red blood cells could have been avoided in serum samples, without compromis-
ing lipid recovery. In addition, lipoprotein particles were not analysed in detail. Therefore, water-
insoluble components other than PLs carried by lipoproteins remained unidentified in autoserum 
preparations, likewise their possible therapeutic effect.
Clinical implications
This was the first series of studies focused on serum PLs and their use in treating horses with sum-
mer eczema. Autoserum treatment showed beneficial effects on this allergic skin disease and was 
convenient to apply in clinical practice since serum PLs could be easily extracted and prepared 
for oral administration. Based on the findings of this thesis and recent literature in human medi-
cine, serum lipoproteins with specific PL species could be an interesting target for further stud-
ies on immune-mediated disorders in horses, especially respiratory tract allergies or autoimmune 
diseases. Accordingly, the utilization of autoserum preparation in the therapy of other allergic 
manifestations should be explored.  
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7 .  C O N C L U S I O N S 
1. This study demonstrated that in Finnhorses summer eczema usually manifests at a  
 young age, and most horses in contact with veterinarians suffer from moderate clinical  
 signs. Severity of clinical signs was not related to either age at onset or duration of  
 disease. 
2. Autologous serum preparation containing the major serum phospholipids was shown 
 to be a favourable method to treat equine summer eczema, with no harmful side effects.
3. Horses with summer eczema had an altered phospholipid profile in their sera compared 
 with healthy horses, and these profiles seemed to change according to the clinical 
 status of the horse. In affected horses, phosphatidylcholine and sphingomyelin were 
 more concentrated in autoserum preparations than they were in healthy horses. Of the 
 major serum phospholipids, sphingomyelin might be a potential link between equine 
 summer eczema and its therapy; however, the causal relation has to be verified 
 in future studies. 
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APPENDIX I
                                      Date__________
Owner
Address
Telephone
Name of the horse
Breed
Gender
Date of birth, country
Colour
Use of the horse
Anamnesis:
Onset of clinical signs
Severity of signs before autoserum treatment:
Itching in the mane
Itching in the tail   
Mild skin lesions in the mane
Mild skin lesions in the tail    
Mild skin lesions in the body
Large skin lesions in the mane
Large skin lesions in the tail    
Large skin lesions in the body
Aggravating factors
Hereditary background
Treatments given and their influence 
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APPENDIX II
FOLLOW-UP                                     Date__________
Owner
Name of the horse
Clinical signs after start of autoserum therapy:
Pruritus: same         
 milder        
 worse        
Skin lesions:  
 same          
 milder        
 worse         
If pruritus has become milder, when has this occurred?
 during the first 2 weeks of therapy    
 during the 1-week pause        
 during the third week of therapy        
 later         
Has the horse been tired during therapy?
 no    
 yes  
If yes: during the first 2 weeks of therapy    
 during the 1-week pause        
 during the third week of therapy        
 later         
 all the time         
Has appetite changed?
 no    
 yes  
Has the horse been exposed to?
 sun           
 insects        
 grass fodder        
Use of autoserum preparation:
Autoserum preparation has been administered:
 about 1 week a month       
 about 1-2 weeks a month       
 about 2-3 weeks a month       
 about daily        
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Indicate the months of medication:
 May        
 June      
 July      
 August      
 September      
 October      
Do you think that your horse has benefited from this therapy relative to the severity of clinical 
signs in earlier summers?
 no benefit     
 some benefit     
 much benefit      
How convenient was this therapy to perform?
 easy      
 rather easy     
 difficult      
Has your horse had some adverse effects from this therapy?
 yes      
 no      
If yes, what kind of effects?
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